WO2007071358A1 - Nicotinic acid derivatives as modulators of metabotropic glutamate receptors - Google Patents

Nicotinic acid derivatives as modulators of metabotropic glutamate receptors Download PDF

Info

Publication number
WO2007071358A1
WO2007071358A1 PCT/EP2006/012181 EP2006012181W WO2007071358A1 WO 2007071358 A1 WO2007071358 A1 WO 2007071358A1 EP 2006012181 W EP2006012181 W EP 2006012181W WO 2007071358 A1 WO2007071358 A1 WO 2007071358A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
methanone
chloro
methyl
piperidin
Prior art date
Application number
PCT/EP2006/012181
Other languages
French (fr)
Inventor
Ralf Glatthar
David Orain
Carsten Spanka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to EP06829702A priority Critical patent/EP1966144A1/en
Priority to CA002627630A priority patent/CA2627630A1/en
Priority to AU2006329007A priority patent/AU2006329007A1/en
Priority to JP2008546217A priority patent/JP2009519986A/en
Priority to BRPI0620066-4A priority patent/BRPI0620066A2/en
Priority to US12/158,387 priority patent/US20090005363A1/en
Publication of WO2007071358A1 publication Critical patent/WO2007071358A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Definitions

  • the present invention relates to novel nicotinic acid derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
  • WO2005/079802 describes bipyridylamides and their use as modulators of metabotropic glutamate receptor-5.
  • the compounds show valuable properties, but also have disadvantages.
  • the invention relates to a compound of formula (I)
  • R 1 represents optionally substituted Alkyl or optionally substituted Benzyl
  • R 2 represents Hydrogen (H), optionally substituted Alkyl or optionally substituted Benzyl; or
  • R 1 and R 2 form together with the Nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms;
  • R 3 represents Halogen, Hydroxy (OH), Alkyl, Alkoxy, Amino, Alkylamino, Dialkylamino;
  • R 4 represents Hydroxy (OH) 1 Halogen, Amino, Alkylamino, Dialkylamino Alkyl, Alkoxy;
  • Q represents CH, CR 4 , N
  • Y represents CH, CR 3 , N;
  • Z represents CR 6a R 6b , NR 5 , O; R s represents Hydrogen, Hydroxy (OH);
  • R 6a and R 6b are each independently selected from Hydrogen, Halogen, Hydroxy (OH), Amino, Alkyl, Alkoxy, Haloalkyl; and provided that Q, V, W are not N at the same time in free base or acid addition salt form for use as a pharmaceutical.
  • the following definitions shall apply if no specific other definition is given:
  • Alkyl represents a straight-chain or branched-chain alkyl group, preferably represents a straight-chain or branched-chain C 1-12 alkyl, particularly preferably represents a straight-chain or branched-chain C ⁇ alkyl; for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert- butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, with particular preference given to methyl, ethyl, n-propyl and iso-propyl.
  • Alkyl may be unsubstituted or substituted. Exemplary substituents include, but are not limited to hydroxyl, alkoxy, halogen and amino. An example of a substituted alkyl is
  • Alkandiyl represents a straight-chain or branched-chain alkandiyl group bound by two different Carbon atoms to the molecule, it preferably represents a straight-chain or branched-chain C 1-12 alkandiyl, particularly preferably represents a straight-chain or branched-chain C 1-6 alkandiyl; for example, methandiyl (-CH 2 -), 1 ,2-ethanediyl (-CH 2 -CH 2 -), 1,1-ethanediyl ((-CH(CH 3 )-), 1 ,1-, 1,2-, 1 ,3-propanediyl and 1 ,1-, 1 ,2-, 1 ,3-, 1 ,4-butanediyl, with particular preference given to methandiyl, 1,1-ethanediyl, 1,2-ethanediyl, 1 ,3- propanediyl, 1 ,4-butanediyl,
  • alkyl part of "alkoxy”, “alkoxyalkyl”, “alkoxycarbonyl”, “alkoxycarbonylalkyl” and “halogenalkyl” shall have the same meaning as described in the above-mentioned definition of "alkyl”.
  • Alkenyl represents a straight-chain or branched-chain alkenyl group and may be substituted or unsubstituted, preferably C 2-6 alkenyl, for example, vinyl, allyl, 1-propenyl, isopropenyl, 2-butenyl, 2-pentenyl, 2-hexenyl, etc. and preferably represents C 2 ⁇ , alkenyl.
  • Alkendiyl may be substituted or unsubstituted
  • Alkynyl represents a straight-chain or branched-chain alkynyl group and may be substituted or unsubstituted, preferably C 2 ⁇ alkynyl, for example, ethenyl, propargyl, 1-propynyl, isopropenyl, 1- (2- or 3) butynyl, 1- (2- or 3) pentenyl, 1- (2- or 3) hexenyl, etc. .
  • Alkynyl may be substituted or unsubstituted.
  • Aryl represents an aromatic hydrocarbon group, preferably a C 6- io aromatic hydrocarbon group; for example phenyl, naphthyl, especially phenyl. Aryl may be substituted or unsubstituted
  • Alkyl denotes an "Aryl” bound to an “Alkyl” (both as defined above) an represents, for example benzyl, ⁇ -methylbenzyl, 2-phenylethyl, oc ⁇ -dimethylbenzyl, especially benzyl.
  • Aralkyl may be substituted or unsubstituted
  • Heterocycle represents a saturated, partly saturated or aromatic ring system containing at least one hetero atom.
  • heterocycles consist of 3 to 11 ring atoms of which 1-3 ring atoms are hetero atoms.
  • Heterocycles may be present as a single ring system or as bicyclic or tricyclic ring systems; preferably as single ring system or as benz-annelated ring system.
  • Bicyclic or tricyclic ring systems may be formed by annelation of two or more rings, by a bridging atom, e.g. Oxygen, sulfur, nitrogen or by a bridging group, e.g. alkandediyl or alkenediyl or be connected by a direct bond.
  • heterocyclic moieties are: pyrrole, pyrroline, pyrrolidine, pyrazole, pyrazoline, pyrazolidine, imidazole, imidazoline, imidazolidine, triazole, triazoline, triazolidine, tetrazole, furane, dihydrofurane, tetrahydrofurane, furazane (oxadiazole), dioxolane, thiophene, dihydrothiophene, tetrahydrothiophene, oxazole, oxazoline, oxazolidine, isoxazole, isoxazoline, isoxazolidine, thiazole, thiazoline, thiazlolidine, isothiazole, istothiazoline, isothiazolidine, thiadiazole, thiadiazoline, thiadiazolidine, pyridine, piperidine, pyridazine, pyrazine
  • indole isoindole, cumarine, cumaronecinoline, isochinoline, cinnoline and the like.
  • ⁇ etero atoms are atoms other than Carbon and Hydrogen, preferably Nitrogen (N), Oxygen (O) or Sulfur (S).
  • Halogen represents Fluoro, Chloro, Bromo or lodo, preferably represents Fluoro, Chloro or Bromo and particularly preferably represents Chloro.
  • Substituted wherever used for a moiety, means that one or more hydrogen atoms in the respective moiety are replaced independently of each other by the corresponding number of substituents.
  • substituents include, but are not limited to hydroxyl, halogen, alkyl, alkoxy and amino.
  • Tautomers can, e.g., be present in cases where amino or hydroxy, each with a least one bound hydrogen, are bound to carbon atoms that are bound to adjacent atoms by double bonds (e.g. keto-enol or imine-enamine tautomerism).
  • the compounds may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures or diastereomeric mixtures. All optical isomers and their mixtures, including the racemic mixtures, are part of the present invention.
  • the invention relates to new compounds of formula (II)
  • Q represents CH, CR 4 , N
  • V represents CH, CR 4 , N
  • W represents CH, CR 4 , N
  • X represents CH, N
  • V represents CH, CR 3 , N;
  • Z represents CR 6a R 6b , NR 5 , O;
  • R 1 represents optionally substituted Alkyl or optionally substituted Benzyl and R 2 represents Hydrogen (H), optionally substituted Alkyl or optionally substituted Benzyl; or
  • R 1 and R 2 form together with the Nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms;
  • R 3 represents Halogen, Hydroxy (OH), Alkyl, Alkoxy, Amino, Alkylamino, Dialkylamino
  • R 4 represents Hydroxy (OH), Halogen, Amino, Alkylamino, Dialkylamino Alkyl, Alkoxy
  • R 5 represents Hydrogen, Hydroxy (OH);
  • R 6a and R 6b are each independently selected from Hydrogen, Halogen, Hydroxy (OH),
  • the invention relates to new compounds of formula (III)
  • Q represents CH, CR 4 , N
  • Z represents CR 6a R 6b , NR 5 , O;
  • R 1 represents optionally substituted Alkyl or optionally substituted Benzyl and R 2 represents Hydrogen (H), optionally substituted Alkyl or optionally substituted Benzyl; or
  • R 1 and R 2 form together with the Nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms;
  • R 3 represents Halogen, Hydroxy (OH), Alkyl, Alkoxy, Amino, Alkylamino, Dialkylamino;
  • R 4 represents Hydroxy (OH), Halogen, Amino, Alkylamino, Dialkylamino Alkyl, Alkoxy;
  • R 5 represents Hydrogen, Hydroxy (OH);
  • R 6a and R 6b are each independently selected from Hydrogen, Halogen, Hydroxy (OH), Amino, Alkyl, Alkoxy, Haloalkyl; and provided that Q, V, W are not N at the same time and provided that at least one Q, V, W represents N, in free base or acid addition salt form.
  • X preferably represents CH.
  • Y preferably represents CH or CR 3 , wherein R 3 preferably represents halogen, particular preferably chloro.
  • R 68 and R 6b if present, preferably are both Hydrogen.
  • Z is preferably selected from NH, CH 2 and O.
  • Z preferably represents NH.
  • R 3 preferably represents Halogen, Alkyl, Alkoxy, Alkylamino, Dialkylamino;
  • R 3 more preferably represents Fluoro, Chloro, C 1-4 alkyl, e.g. methyl.
  • R 3 particularly preferably represents chloro.
  • R 4 preferably represents Hydroxy (OH), Halogen, Alkyl, Alkoxy.
  • R 4 particularly preferably represents alkyl, e.g. methyl or Haloalkyl (substituted alkyl), e.g. trifluoromethyl.
  • R 1 and R 2 form together with the Nitrogen atom to which they are attached particularly preferably represent an unsubstituted, a single or twofold substituted heterocycle having 5 - 9 ring atoms and 1 - 3 hetero atoms; the hetero atoms being selected from the group consisting of N, O; the substituents being selected from the group consisting of Halogen, C 1-4 Alkyl.
  • R 1 and R 2 form together with the Nitrogen atom to which they are attached very particularly preferably represent an unsubstituted, a single or twofold substituted heterocycle selected from the group consisting of
  • halogen e.g. fluoro, chloro
  • alkyl e.g. methyl, ethyl, propyl, butyl
  • haloalkyl e.g. trifluormethyl, fluoropropyl, difluoropropyl, e.g. 1 ,1-difluoropropyl or 1 ,2-difluoropropyl.
  • the substituents may be on the same or different in-ring atoms.
  • R 1 and R 2 preferably represent, independent from each other, Ci-C 4 alkyl or benzyl, optionally substituted by Ci-C 4 alkoxy or halogen.
  • radical definitions apply both to the end products of the formulae (I) , (II), (III) and (IV) and also, correspondingly, to the starting materials or intermediates required in each case for the preparation.
  • These radical definitions can be combined with one another at will, i.e. including combinations between the given preferred ranges. Further, individual definitions may not apply.
  • R 4 represents C 1 -C 4 BIkVl, preferably methyl and the other substituents have the meaning given in this specification.
  • R 4 represents halogen; C 1 -C 4 BIkVl, preferably methyl and the other substituents have the meaning given in this specification.
  • R 4 represents C ⁇ C ⁇ Ikyl; hal looggeeni , preferably chloro and the other substituents have the meaning given in this specification, including the preferences mentioned herein.
  • a particularly preferred class of compounds have the formulae (IV):
  • R 1 and R 2 form together with the Nitrogen atom to which they are attached very particularly preferably represent a heterocycle, as described herein.
  • the heterocycle is unsubstituted, a single or twofold substituted.
  • R 3 is preferably halogen, e.g. chloro.
  • R 4 is preferably alkyl, e.g. methyl.
  • the invention provides process for the production of the compounds of formulae (I), (II), (III) and (IV) and their salts.
  • a first process wherein Z represents NH or O, comprises the step of reacting a compound of formula (ii)
  • LG represents a leaving group such as Chlorine, Fluorine, methoxy, preferably chlorine, with a compound of formula (iii)
  • Such a process can be effected according to conventional methods, e.g. by aromatic nucleophilic substitution under acidic conditions as described in example 1.
  • the reaction is carried out under basic conditions in the presence or absence of a transition metal catalyst, e.g. by using for example potassium tert.-butoxide as base and palladium(ll) acetate / BINAP catalyst as described in example 2.
  • Such a process can be performed by transforming acid (v) into an acyl halide (e.g. by thionyl chloride) which is then reacted with the desired amine (iv) to give (I) as outlined in example 4.
  • acid (v) can be activated by a peptide coupling agent (e.g. HATU) and then converted to (I) by addition of an amine (iv) as shown in example 5.
  • a further process for making compounds of the present invention, wherein Z represents CH 2 comprises the step of reacting a compound of formula (ii)
  • LG represents a leaving group such as Chlorine, Fluorine, methoxy, preferably chlorine, with a compound of formula (vi)
  • Q, V, W is as defined above, optionally in the presence of a reaction auxiliary, such as a Zn / Ni(II) catalyst, e.g. Zn / NiCI 2 (bisphosphine),
  • One or more functional groups may need to be protected in the starting materials by protecting groups.
  • the protecting groups employed may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products.
  • the specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned hereinabove and hereinafter.
  • Acid addition salts may be produced from the free bases in known manner, and vice- versa.
  • Compounds of formulae (I), (II), (III) and (IV) in optically pure form can be obtained from the corresponding racemates according to well-known procedures, e.g. HPLC with chiral matrix. Alternatively, optically pure starting materials can be used.
  • Stereoisomeric mixtures e.g. mixtures of diastereomers
  • Diastereomeric mixtures for example may be separated into their individual diastereomers by means of fractionated crystallization, chromatography, solvent distribution, and similar procedures. This separation may take place either at the level of a starting compound or in a compound of formula I itself.
  • Enantiomers may be separated through the formation of diastereomeric salts, for example by salt formation with an enantiomer-pure chiral acid, or by means of chromatography, for example by HPLC, using chromatographic substrates with chiral ligands.
  • Suitable diluents for carrying out the above- described are especially inert organic solvents. These include, in particular, aliphatic, alicyclic or aromatic, optionally halogenated hydrocarbons, such as, for example, benzine, benzene, toluene, xylene, chlorobenzene, dichlorobenzene, petroleum ether, hexane, cyclohexane, dichloromethane, chloroform, carbon tetrachloride; ethers, such as diethyl ether, diisopropyl ether, dioxane, tetrahydrofuran or ethylene glycol dimethyl ether or ethylene glycol diethyl ether; ketones, such as acetone, butanone or methyl isobutyl ketone; nitriles, such as acetonitrile propionitrile or butyronitrile; amides, such as N.N-dimethylformamide, N 1
  • mixtures of diluents may be employed.
  • water or diluents constaining water may be suitable. It is also possible to use one a starting material as diluent simultaneously.
  • Reaction temperatures can be varied within a relatively wide range.
  • the processes are carried out at temperatures between 0 0 C and 150 0 C, preferably between 10 0 C and 120 0 C.
  • Deprotonation reactions can be varied within a relatively wide range.
  • the processes are carried out at temperatures between -150°C and +50°C, preferably between -75°C and 0°C.
  • a compound of formulae (I), (II), (III) and (IV) obtained according to the above described processes can be converted into another compound formulae (I), (II), (III) and (IV) according to conventional methods.
  • agents of the invention exhibit valuable pharmacological properties and are therefore useful as pharmaceuticals.
  • the agents of the invention exhibit a marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs).
  • mGluRs human metabotropic glutamate receptors
  • This can be determined in vitro for example at recombinant human metabotropic glutamate receptors, especially PLC-coupled subtypes thereof such as mGluR5, using different procedures like, for example, measurement of the inhibition of the agonist induced elevation of intracellular Ca 2+ concentration in accordance with L. P. Daggett et al., Neuropharm. Vol. 34, pages 871-886 (1995), P. J. Flor et al., J. Neurochem. Vol.
  • the agents of the invention are therefore useful in the treatment of disorders associated with irregularities of the glutamatergic signal transmission, and of nervous system disorders mediated full or in part by mGluR5.
  • the agents of the invention are therefore useful in the prevention, treatment or delay of progression of disorders associated with irregularities of the glutamatergic signal transmission, of the gastro-intestinal and urinary tract and of nervous system disorders mediated full or in part by mGluR5.
  • disorders associated with irregularities of the glutamatergic signal transmission are for example epileptogenesis including neuronal protection after status epilepticus, cerebral ischemias, especially acute ischemias, ischemic diseases of the eye, muscle spasms such as local or general spasticity, skin disorders, obesity disorders and, in particular, convulsions or pain.
  • GSD Gastro-Esophageal Reflux Disease
  • Functional Gastro-intestinal Disorders include Post-operative Ileus.
  • FGIDs Functional Gastro-intestinal Disorders
  • FD functional dyspepsia
  • GERD functional heartburn
  • IBS irritable bowel syndrome
  • functional bloating functional diarrhea, chronic constipation, functional disturbancies of the biliary tract as well as other conditions according to Gut 1999; Vol. 45 Suppl. II.
  • Post-operative Ileus is defined as failure of aboral passage of intestinal contents due to transient impairment of Gl motility following abdominal surgery.
  • disorders of the Urinary Tract comprise conditions associated with functional disturbancies and/or discomfort/pain of the urinary tract.
  • disorders of the urinary tract include but are not limited to incontinence, benign prostatic hyperplasia, prostatitis, detrusor hyperreflexia, outlet obstruction, urinary frequency, nocturia, urinary urgency, overactive bladder (OAB), pelvic hypersensitivity, urge incontinence, urethritis, prostatodynia, cystitis, idiopathic bladder hypersensitivity and the like.
  • OAB is a syndrome characterized by urgency, with or without urinary incontinence, and usually with increased voiding frequency and nocturia.
  • Nervous system disorders mediated full or in part by mGluR5 are for example acute, traumatic and chronic degenerative processes of the nervous system, such as Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis and fragile X syndrome, substance-related disorders, psychiatric diseases such as schizophrenia, affective and anxiety disorders, attention deficit disorders and cognitive dysfunction associated with these and other CNS disorders.
  • Substance-related disorders include substance abuse, substance dependence and substance withdrawal disorders.
  • Anxiety disorders includes panic disorder, social and specific phobias, anxiety, obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD) and generalized anxiety disorder (GAD).
  • Affective disorders include depressive (major depression, dysthymia, depressive disorders NOS) and bipolar disorders (bipolar I and Il disorders).
  • Cognitive dysfunction associated with these and other CNS disorders include deficits and abnormalities in attention and vigilance, executive functions and memory (for instance working memory and episodic memory).
  • Other disorders which are mediated fully or in part are pain and itch.
  • a further disorder is migraine.
  • Activity of the agents of the invention in anxiety can be demonstrated in standard models such as the stress-induced hyperthermia in mice [cf. A. Lecci et al., Psychopharmacol. 101 , 255-261].
  • selected agents of the invention reverse the stress-induced hyperthermia.
  • selected agents of the invention show reversal of Freund complete adjuvant (FCA) induced hyperalgesia [cf. J. Donnerer et al., Neuroscience 49, 693-698 (1992) and CJ. Woolf, Neuroscience 62, 327-331 (1994)].
  • FCA Freund complete adjuvant
  • TLESRs gastric distension-induced transient lower esophageal sphincter relaxations
  • Agents of the invention in functional dyspepsia can be demonstrated a model of fasted gastric tone and gastric accommodation to meal in dogs.
  • selected agents of the invention increase the gastric volume in fasting conditions indicative of a reduced gastric tone.
  • agents of the invention in visceral hyperalgesia can be demonstrated in standard rat models according to modified methods by Tarrerias, A. et al., Pain (2002) 100: 91-97, Schwetz, I. et al., Am. J. Physiol. (2005) 286: G683-G691 , of La, J. et al., World J. Gastroenterol. (2003) 9: 2791-2795.
  • selected agents of the invention reduce the exaggerated abdominal striated muscle contractions, indicative of a visceral antinociceptive activity.
  • agents of the invention in visceral sensation/pain of the urinary bladder can be demonstrated in a standard mouse model according to a modified method by Ness TJ and Elhefni H. J Urol. (2004) 171 :1704-8.
  • selected agents of the invention reduce the EMG (visceromotor) response, indicative of a visceral antinociceptive and /or hyposensitivity.
  • agents of the invention in overactive bladder and urge incontinence can be demonstrated in standard cystometry models in rats according to modified method by Tagaki-Matzumoto et al J. Pharmacol. Sci. (2004) 95 : 458-465.
  • selected agents of the invention increased threshold volumes eliciting bladder contractions indicative of therapeutic potential in conditions with bladder dysfunctions.
  • the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.05 to about 100 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 5 to 1500 mg, preferably about 10 to about 1000 mg of the compound conveniently administered in divided doses up to 4 times a day or in sustained release form.
  • the present invention also provides in a further aspect an agent of the invention for use as a pharmaceutical, e.g. in the treatment of disorders associated with irregularities of the glutamatergic signal transmission, and of nervous system disorders mediated full or in part by mGluR5.
  • the invention also provides the use of an agent of the invention, in the treatment of disorders associated with irregularities of the glutamatergic signal transmission, and of nervous system disorders mediated full or in part by mGluR5.
  • the invention provides the use of compounds of formula (I) as modulators of metabotropic Glutamate Receptors, Subtype 5 ("mGluR5 - Modulators").
  • the invention provides the use of an agent of the invention for the manufacture of a pharmaceutical composition designed for the treatment of disorders associated with irregularities of the glutamatergic signal transmission, and of nervous system disorders mediated full or in part by mGluR5.
  • the invention relates to a method of treating disorders mediated full or in part by mGluR5, which method comprises administering to a warm-blooded organism in need of such treatment a therapeutically effective amount of an agent of the invention.
  • compositions comprising an agent of the invention in association with one or more pharmaceutical carrier or one or more pharmaceutically acceptable diluent.
  • the pharmaceutical compositions according to the invention are compositions for enteral, such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (human beings and animals) that comprise an effective dose of the pharmacological active ingredient alone or together with a significant amount of a pharmaceutically acceptable carrier.
  • the dose of the active ingredient depends on the species of warm-blooded animal, body weight, age and individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
  • compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient.
  • Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragees, tablets or capsules.
  • compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
  • properly isotope-labeled agents of the invention exhibit valuable properties as histopathological labeling agents, imaging agents and/or biomarkers, hereinafter "markers", for the selective labeling of the metabotropic glutamate receptor subtype 5 (mGlu5 receptor). More particularly the agents of the invention are useful as markers for labeling the central and peripheral mGlu5 receptors in vitro or in vivo.
  • compounds of the invention which are properly isotopically labeled are useful as PET markers.
  • PET markers are labeled with one or more atoms selected from the group consisting of 11 C, 13 N, 15 0, 18 F.
  • the agents of the invention are therefore useful, for instance, for determining the levels of receptor occupancy of a drug acting at the mGlu5 receptor, or diagnostic purposes for diseases resulting from an imbalance or dysfunction of mGlu ⁇ receptors, and for monitoring the effectiveness of pharmacotherapies of such diseases.
  • the present invention provides an agent of the invention for use as a marker for neuroimaging.
  • the present invention provides a composition for labeling brain and peripheral nervous system structures involving mGlu5 receptors in vivo and in vitro comprising an agent of the invention.
  • the present invention provides a method for labeling brain and peripheral nervous system structures involving mGlu5 receptors in vitro or in vivo, which comprises contacting brain tissue with an agent of the invention.
  • the method of the invention may comprise a further step aimed at determining whether the agent of the invention labeled the target structure.
  • Said further step may be effected by observing the target structure using positron emission tomography (PET) or single photon emission computed tomography (SPECT), or any device allowing detection of radioactive radiations.
  • PET positron emission tomography
  • SPECT single photon emission computed tomography
  • System 1 System 1: Performed on a Waters system equipped with a CTC Analytics HTS PAL autosampler, 515 pumps, and a 996 DAD detector operating at 210 nm.
  • System 5 Agilent 1100 Series, LC-MSD and a Agilent Zorbax SB-C18 3x30mm 1.8 ⁇ m Column running a gradient Water + 0.05% TFA / Acetonitrile + 0.05% TFA from 70/30 to 0/100 over 3.25 1 - 0/100 over 0.75' - 0/100 to 60/40 over 0.25' with a flux of 0.7 ml/min, 35°C.
  • System 6 Agilent 1100 Series, LC-MSD and a Agilent Zorbax SB-C18 3x30mm 1.8 ⁇ m
  • Example 1.1 6-(4-Chloro-phenylamino)-N, N-diethyl-nicotinamide hydrochloride 6-Chloro-N,N-diethyl-nicotinamide (100 mg, 0.47 mmol) and 4-chloroaniline (184 mg, 1.41 mmol) are suspended in a mixture of glacial acetic acid (0.6 mL) and water (1.4 mL). The reaction mixture is heated in a sealed 3 mL-vial to 100 0 C over night. After reaching room temperature the reaction mixture is poured onto MTBE (30 mL) and extracted with 2M HCI (3x 5 mL).
  • the combined acidic extracts are made alkaline by addition of 2M NaOH (10 mL) extracted with MTBE (3x 15 mL).
  • the combined organic extracts are dried (Na 2 SO 4 ) and evaporated to dryness to.
  • the residue is purified by flash-chromatography. To the combined product containing fractions is added 4M HCI in dioxane (0.25 mL) followed by evaporation. The residue is triturated with ether, filtered off, washed with cold ether and vacuum dried at 45 0 C to give the title compound as colorless crystals (90 mg, 56%).
  • the starting material can be prepared as described hereafter:
  • chloronicotinoyl chloride (4 g, 22 mmol) is suspended in DCM (40 mL).
  • DCM dimethylethyl sulfoxide
  • the reaction flask is placed in an ice bath and a solution of diethylamide (2.31 mL, 22 mmol) and triethylamine (3.90 mL, 27.8 mmol) in DCM (40 mL) is added within 45 min keeping the internal temperature below 5 0 C.
  • the ice bath is removed and the reaction mixture is stirred for further 30 min.
  • Example 1.12 rac-[6-(4-Chloro-Dhenvlamino)-Dvridin-3-vl]-(3-methyl-DiDeridin-1-vl)- methanone
  • Example 1.12a f6-(4-Chloro-Dhenvlamino)-Dvridin-3-vl1-(S-3-methvl-piDeridin-1-vl)- methanone
  • Example 2.2 Azepan- 1 -yl-[6-(pyridin-3-ylamino) -pyridin-3-yl]-methanone
  • Example 2.10b fS-Chloro- ⁇ -f ⁇ -methyl-pvridin-d-ylaminoi-pv ⁇ dm-S-vlMRS-methvl-piperidin- 1-yl)-methanone
  • the starting material was prepared as described hereafter:
  • 3-Ethyl pyridine (5.0 g, 46.7 mmol) was hydrogenated in AcOH (100 ml.) over PtO 2 (500 mg) under 4 bar for 4 hours. The mixture was filtered through a pad of celite and washed with AcOH. The solvent was removed in vacuo and the residue was dissolved into water. The solution was basified by addition with 40% NaOH solution. The aqueous phase was extracted with Et 2 O. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford 3-ethyl piperidine (4.4 g, 83%) as a clear yellow oil.
  • the starting material was prepared as described hereafter:
  • 3-propyl pyridine (300 mg, 2.48 mmol) was hydrogenated in AcOH (20 mL) over PtO 2 (50 mg) under 4 bar for 16 hours. The mixture was filtered through a pad of celite and washed with AcOH. The solvent was removed in vacuo and the residue was dissolved into water. The solution was basified by addition with 40% NaOH solution. The aqueous phase was extracted with Et 2 O. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford 3-propyl piperidine (300 mg, 95%) as a clear yellow oil.
  • Example 2.24 ⁇ 5-Chloro-6-(6-methoxv-Dvridin-3-vlamino)-Dvridin-3-vll-((R)-2-ethvl-DiDeridin- 1-yl)-methanone
  • the starting material can be prepared as described hereafter:
  • the starting material can be prepared as described hereafter:
  • 3-Cyclopropyl pyridine (820 mg, 5.27 mmol) was hydrogenated in a mixture of MeOH (15mL) and concentrated aqueous hydrochloric acid (0.58 mL) in the presence of Nishimura catalyst (70 mg) under atmospheric pressure for 22 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM.
  • Example 4.36 f5-Chloro-6-(6-methvl-pvridtn-3-vlarnino)-pvridin-3-vlh((R)-2-propyl-piperidin- 1-yl)-methanone
  • R, 0.61 (DCM/MeOH 5:1 )
  • HPLC: t R 2.97 min (system 4);
  • LC/MS MS: m/z 373 (MH + )
  • the starting material was prepared as described hereafter:
  • 2-Ethyl-3-methylpyridine was prepared by Suzuki coupling of 2-bromo-3-methylpyridine and ethylboronic acid according to the procedure given in Tetrahedron Letters 2002, 43, 6987- 6990. The desired product was obtained in 52% yield after purification on silica gel. ii) 2-Etyhl-3-methyl-piperidine hydrochloride
  • 2-Ethyl-3-methyl pyridine (1.75 g, 11.1 mmol) was hydrogenated in a mixture of MeOH (32 mL) and concentrated aqueous hydrochloric acid (1.2 ml_) in the presence of Nishimura catalyst (180 mg) under atmospheric pressure for 22 hours.
  • the mixture was filtered through a pad of celite and washed with MeOH.
  • the solvent was removed in vacuo and the residue was dissolved in water.
  • the aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM.
  • the starting material was prepared as described hereafter:
  • 5-Methyl-2-propyl-pyridine was prepared by Suzuki coupling of 2-bromo-5-methylpyridine and propylboronic acid according to the procedure given in Tetrahedron Letters 2002, 43, 6987-6990.
  • the desired product was obtained in 24% yield after purification on silica gel.
  • 5-Methyl-2-propyl-pyridine (345 mg, 2.55 mmol) was hydrogenated in a mixture of MeOH (10 mL) and concentrated aqueous hydrochloric acid (0.29 mL) in the presence of Nishimura catalyst (50 mg) under atmospheric pressure for 40 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM.
  • the starting material was prepared as described hereafter:
  • 5-Fluoro-2-propyl pyridine (182 mg, 1.04 mmol) was hydrogenated in a mixture of MeOH (10 mL) and concentrated aqueous hydrochloric acid (0.13 mL) in the presence of Nishimura catalyst (50 mg) at 4 bar for 3.5 hours.
  • the mixture was filtered through a pad of celite and washed with MeOH.
  • the solvent was removed in vacuo and the residue was dissolved in water.
  • the aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM.
  • Example 4.63 f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pyridin-3-yll-f2-(1,2-difluoro-propyl)- piperidin-1-yl]-methanone and
  • Example 4.64 [5-Chloro-6-(6-methyl-pyridin-3-ylamino)- pyhdin-3-yl]-[2-(2-fluoro-propyl) -piperidin- 1 -yl]-methanone
  • the starting material was prepared as described hereafter:
  • the aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM.
  • the organic phases were combined, dried over sodium sulfate, acidified by addition of ethanolic hydrochloric acid, and concentrated in vacuo to afford a mixture of 2-(1 ,2-difluoro-propyl)- piperidine hydrochloride, 2-(1-fluoro-propyl)-piperidine hydrochloride and 2-propyl-piperidine hydrochloride as light red solid (100%) which was used in the next step without further purification.
  • the starting material can be prepared as described hereafter.
  • Example 5.2 rac-f5-Chloro-6-(4-chloro-phenvlamino)-pvridin-3-yll-(3-methvl-piperidin-1-yl)- methanone
  • Example 5.2a f5-Chloro-6-(4-chloro-phenvlamino)-pyridin-3-yll-(S-3-methyl-piperidin-1-yl)- methanone
  • Example 6.1 Azepan-1-vl-[6-(4-chloro-phenvlamino)-5-methoxv-pyridin-3-vll-methanone
  • azepan-1-yl-(6-chloro-5-methoxy-pyridin-3-yl)-methanone 198 mg, 0.70 mmol
  • 4-chloroaniline 270 mg, 2.11 mmol
  • finely ground anhydrous K 2 CO 3 (491 mg, 3.52 mmol).
  • a still warm solution prepared by dissolving palladium(ll) acetate (10 mg, 0.04 mmol) and BINAP (27 mg,
  • the starting material can be prepared as described hereafter:
  • Example ⁇ .2 Azepan-1-yl-f5-methoxv-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll- methanone]
  • the starting material can be prepared as described hereafter:
  • the starting material can be prepared as described hereafter:
  • 6-(4-Chloro-phenylamino)-pyridazine-3-carboxylic acid A solution of e-chloropyridazine-S-carboxylic acid (0.5 g, 3.15 mmol, [5096-73-1]) and 4- chloroaniline (805 mg, 6.31 mmol) in 1 ,2-dimethoxyethane (5 mL) is microwave heated for 20 min at 100 0 C. After cooling the reaction mixture is diluted with ethyl acetate (10 mL) and stirred for 5 min. The brown precipitate is filtered off and triturated with cold water (30 mL). The light brown suspension is filtered and washed with water. After vacuum dry at 45°C the product is obtained as a beige powder (250 mg, 32%).
  • the starting material was prepared as described hereafter:
  • Example 9.2 r5-Fluoro-6-(6-methvl-pvridin-3-ylamino)-pyridin-3-yll ⁇ piperidin-1-yl-methanone [5-Fluoro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-piperidin-1 -yl-methanone was prepared following the procedure described in example 9.1.
  • the starting material can be prepared as described in example 9.1.v) and iv) starting from 6- Chloro-5-fluoro-nicotinic acid methyl ester.
  • Example 10 Biological Testing. Activity of compounds of the present invention was examined by measurement of the inhibition of the glutamate induced elevation of intracellular Ca 2* -concentration following similar methods than those described in L. P. Daggett et al., Neuropharm. Vol. 34, pages 871-886 (1995), P. J. Flor et al., J. Neurochem. Vol. 67, pages 58-63 (1996).
  • the table below represents percentages of inhibition of the glutamate induced elevation of intracellular Ca ,2+ -concentration at a concentration of 10 ⁇ M.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to novel nicotinic acid derivatives, of formula (I), wherein the substituents are defined in the specification, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.

Description

NICOTINIC ACID DERIVATIVES AS MODULATORS OF MΞTABOTROPIC GLUTAMATE RECEPTORS
The present invention relates to novel nicotinic acid derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
WO2005/079802 describes bipyridylamides and their use as modulators of metabotropic glutamate receptor-5. The compounds show valuable properties, but also have disadvantages. Thus, there is a need to provide further compounds having properties as modulators of metabotropic glutamate receptor-5.
In a first aspect, the invention relates to a compound of formula (I)
Figure imgf000002_0001
wherein R1 represents optionally substituted Alkyl or optionally substituted Benzyl and
R2 represents Hydrogen (H), optionally substituted Alkyl or optionally substituted Benzyl; or
R1 and R2 form together with the Nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms; R3 represents Halogen, Hydroxy (OH), Alkyl, Alkoxy, Amino, Alkylamino, Dialkylamino;
R4 represents Hydroxy (OH)1 Halogen, Amino, Alkylamino, Dialkylamino Alkyl, Alkoxy;
Q represents CH, CR4, N;
V represents CH, CR4, N; W represents CH1 CR4, N; X represents CH1 N;
Y represents CH, CR3, N;
Z represents CR6aR6b, NR5, O; Rs represents Hydrogen, Hydroxy (OH);
R6a and R6b are each independently selected from Hydrogen, Halogen, Hydroxy (OH), Amino, Alkyl, Alkoxy, Haloalkyl; and provided that Q, V, W are not N at the same time in free base or acid addition salt form for use as a pharmaceutical. In the present specification, the following definitions shall apply if no specific other definition is given:
"Alkyl" represents a straight-chain or branched-chain alkyl group, preferably represents a straight-chain or branched-chain C1-12alkyl, particularly preferably represents a straight-chain or branched-chain C^alkyl; for example, methyl, ethyl, n- or iso-propyl, n-, iso-, sec- or tert- butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, with particular preference given to methyl, ethyl, n-propyl and iso-propyl. Alkyl may be unsubstituted or substituted. Exemplary substituents include, but are not limited to hydroxyl, alkoxy, halogen and amino. An example of a substituted alkyl is trifluoromethyl.
"Alkandiyl" represents a straight-chain or branched-chain alkandiyl group bound by two different Carbon atoms to the molecule, it preferably represents a straight-chain or branched-chain C1-12 alkandiyl, particularly preferably represents a straight-chain or branched-chain C1-6 alkandiyl; for example, methandiyl (-CH2-), 1 ,2-ethanediyl (-CH2-CH2-), 1,1-ethanediyl ((-CH(CH3)-), 1 ,1-, 1,2-, 1 ,3-propanediyl and 1 ,1-, 1 ,2-, 1 ,3-, 1 ,4-butanediyl, with particular preference given to methandiyl, 1,1-ethanediyl, 1,2-ethanediyl, 1 ,3- propanediyl, 1 ,4-butanediyl.
Each alkyl part of "alkoxy", "alkoxyalkyl", "alkoxycarbonyl", "alkoxycarbonylalkyl" and "halogenalkyl" shall have the same meaning as described in the above-mentioned definition of "alkyl".
"Alkenyl" represents a straight-chain or branched-chain alkenyl group and may be substituted or unsubstituted, preferably C2-6alkenyl, for example, vinyl, allyl, 1-propenyl, isopropenyl, 2-butenyl, 2-pentenyl, 2-hexenyl, etc. and preferably represents C2^, alkenyl.
"Alkendiyl" represents a straight-chain or branched-chain alkendiyl group bound by two different Carbon atoms to the molecule, it preferably represents a straight-chain or branched-chain C2^ alkandiyl; for example, -CH=CH-, -CH=C(CH3)-, -CH=CH-CH2-, - C(CHa)=CH-CH2-, -CH=C(CH3)-CH2-, -CH=CH-C(CH3)H-, -CH=CH-CH=CH-, -C(CH3)=CH- CH=CH-, -CH=C(CH3)-CH=CH-, with particular preference given to -CH=CH-CH2-, -CH=CH- CH=CH-. Alkendiyl may be substituted or unsubstituted "Alkynyl" represents a straight-chain or branched-chain alkynyl group and may be substituted or unsubstituted, preferably C2^alkynyl, for example, ethenyl, propargyl, 1-propynyl, isopropenyl, 1- (2- or 3) butynyl, 1- (2- or 3) pentenyl, 1- (2- or 3) hexenyl, etc. .preferably represents C2^alkynyl and particularly preferably represents ethynyl. Alkynyl may be substituted or unsubstituted.
"Aryl" represents an aromatic hydrocarbon group, preferably a C6-io aromatic hydrocarbon group; for example phenyl, naphthyl, especially phenyl. Aryl may be substituted or unsubstituted
"Aralkyl" denotes an "Aryl" bound to an "Alkyl" (both as defined above) an represents, for example benzyl, α-methylbenzyl, 2-phenylethyl, ocα-dimethylbenzyl, especially benzyl. Aralkyl may be substituted or unsubstituted
"Heterocycle" represents a saturated, partly saturated or aromatic ring system containing at least one hetero atom. Preferably, heterocycles consist of 3 to 11 ring atoms of which 1-3 ring atoms are hetero atoms. Heterocycles may be present as a single ring system or as bicyclic or tricyclic ring systems; preferably as single ring system or as benz-annelated ring system. Bicyclic or tricyclic ring systems may be formed by annelation of two or more rings, by a bridging atom, e.g. Oxygen, sulfur, nitrogen or by a bridging group, e.g. alkandediyl or alkenediyl or be connected by a direct bond. A Heterocycle may be substituted by one or more substituents selected from the group consisting of Oxo (=O), Halogen, Nitro, Cyano, Alkyl, Alkandiyl, Alkenediyl, Alkoxy, Alkoxyalkyl, Alkoxycarbonyl, Alkoxycarbonylalkyl, Halogenalkyl, Aryl, Aryloxy, Arylalkyl. Examples of heterocyclic moieties are: pyrrole, pyrroline, pyrrolidine, pyrazole, pyrazoline, pyrazolidine, imidazole, imidazoline, imidazolidine, triazole, triazoline, triazolidine, tetrazole, furane, dihydrofurane, tetrahydrofurane, furazane (oxadiazole), dioxolane, thiophene, dihydrothiophene, tetrahydrothiophene, oxazole, oxazoline, oxazolidine, isoxazole, isoxazoline, isoxazolidine, thiazole, thiazoline, thiazlolidine, isothiazole, istothiazoline, isothiazolidine, thiadiazole, thiadiazoline, thiadiazolidine, pyridine, piperidine, pyridazine, pyrazine, piperazine, triazine, pyrane, tetrahydropyrane, thiopyrane, tetrahydrothiopyrane, oxazine, thiazine, dioxine, morpholine, purine, pterine, and the corresponding benz-annelated heterocycles, e.g. indole, isoindole, cumarine, cumaronecinoline, isochinoline, cinnoline and the like. Ηetero atoms" are atoms other than Carbon and Hydrogen, preferably Nitrogen (N), Oxygen (O) or Sulfur (S).
"Halogen" represents Fluoro, Chloro, Bromo or lodo, preferably represents Fluoro, Chloro or Bromo and particularly preferably represents Chloro.
"Substituted", wherever used for a moiety, means that one or more hydrogen atoms in the respective moiety are replaced independently of each other by the corresponding number of substituents. Exemplary substituents include, but are not limited to hydroxyl, halogen, alkyl, alkoxy and amino.
Compounds of formulae (I), (II), (III) or (IV) may exist in free or acid addition salt form. In this specification, unless otherwise indicated, language such as "compounds of formula (I)", for example is to be understood as embracing the compounds in any form, for example free base or acid addition salt form. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds of formula (I), (II), (III) or (IV), such as picrates or perchlorates, are also included. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and are therefore preferred.
Tautomers can, e.g., be present in cases where amino or hydroxy, each with a least one bound hydrogen, are bound to carbon atoms that are bound to adjacent atoms by double bonds (e.g. keto-enol or imine-enamine tautomerism).
On account of the asymmetrical carbon atom(s) that may be present in the compounds of formulae (I), (II), (III) or (IV) and their salts, the compounds may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures or diastereomeric mixtures. All optical isomers and their mixtures, including the racemic mixtures, are part of the present invention.
In a further aspect, the invention relates to new compounds of formula (II)
Figure imgf000005_0001
(II) wherein
Q represents CH, CR4, N;
V represents CH, CR4, N; W represents CH, CR4, N;
X represents CH, N;
V represents CH, CR3, N;
Z represents CR6aR6b, NR5, O;
R1 represents optionally substituted Alkyl or optionally substituted Benzyl and R2 represents Hydrogen (H), optionally substituted Alkyl or optionally substituted Benzyl; or
R1 and R2 form together with the Nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms;
R3 represents Halogen, Hydroxy (OH), Alkyl, Alkoxy, Amino, Alkylamino, Dialkylamino; R4 represents Hydroxy (OH), Halogen, Amino, Alkylamino, Dialkylamino Alkyl, Alkoxy;
R5 represents Hydrogen, Hydroxy (OH);
R6a and R6b are each independently selected from Hydrogen, Halogen, Hydroxy (OH),
Amino, Alkyl, Alkoxy, Haloalkyl; and provided that Q, V, W are not N at the same time and provided that at least one Q, V, W represents N, in free base or acid addition salt form.
In yet a further aspect, the invention relates to new compounds of formula (III)
Figure imgf000006_0001
wherein
Q represents CH, CR4, N;
V represents CH, CR4, N; W represents CH, CR4, N; X represents CH, N; Y represents CR3;
Z represents CR6aR6b, NR5, O;
R1 represents optionally substituted Alkyl or optionally substituted Benzyl and R2 represents Hydrogen (H), optionally substituted Alkyl or optionally substituted Benzyl; or
R1 and R2 form together with the Nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms; R3 represents Halogen, Hydroxy (OH), Alkyl, Alkoxy, Amino, Alkylamino, Dialkylamino; R4 represents Hydroxy (OH), Halogen, Amino, Alkylamino, Dialkylamino Alkyl, Alkoxy; R5 represents Hydrogen, Hydroxy (OH);
R6a and R6b are each independently selected from Hydrogen, Halogen, Hydroxy (OH), Amino, Alkyl, Alkoxy, Haloalkyl; and provided that Q, V, W are not N at the same time and provided that at least one Q, V, W represents N, in free base or acid addition salt form.
Preferred substituents, preferred ranges of numerical values or preferred ranges of the radicals present in the formula (I), (II) and (III) and the corresponding intermediate compounds are defined below.
X preferably represents CH.
Y preferably represents CH or CR3, wherein R3 preferably represents halogen, particular preferably chloro.
R68 and R6b , if present, preferably are both Hydrogen.
Z is preferably selected from NH, CH2 and O.
Z preferably represents NH.
R3 preferably represents Halogen, Alkyl, Alkoxy, Alkylamino, Dialkylamino;
R3 more preferably represents Fluoro, Chloro, C1-4 alkyl, e.g. methyl.
R3 particularly preferably represents chloro.
R4 preferably represents Hydroxy (OH), Halogen, Alkyl, Alkoxy. R4 particularly preferably represents alkyl, e.g. methyl or Haloalkyl (substituted alkyl), e.g. trifluoromethyl.
R1 and R2 form together with the Nitrogen atom to which they are attached preferably represent an unsubstituted or substituted heterocycle having 3 - 11 ring atoms and 1 - 4 hetero atoms; the hetero atoms being selected from the group consisting of N, O, S, the substituents being selected from the group consisting of Oxo (=O), Hydroxy, Halogen, Amino, Nitro, Cyano, C1^ Alkyl, C1-4 Alkoxy, C1-4 Alkoxyalkyl, C1^ Alkoxycarbonyl, C1^ Alkoxycarbonylalkyl, C1-4 Halogenalkyl, C6-10 Aryl, Halogen- C6-1O Aryl, C6-10 Aryloxy, C6-10-ArVl-C1 Λ alkyl.
R1 and R2 form together with the Nitrogen atom to which they are attached particularly preferably represent an unsubstituted, a single or twofold substituted heterocycle having 5 - 9 ring atoms and 1 - 3 hetero atoms; the hetero atoms being selected from the group consisting of N, O; the substituents being selected from the group consisting of Halogen, C1-4 Alkyl.
R1 and R2 form together with the Nitrogen atom to which they are attached very particularly preferably represent an unsubstituted, a single or twofold substituted heterocycle selected from the group consisting of
Figure imgf000008_0001
and the substituents being selected from the group consisting of halogen, e.g. fluoro, chloro; alkyl, e.g. methyl, ethyl, propyl, butyl; haloalkyl, e.g. trifluormethyl, fluoropropyl, difluoropropyl, e.g. 1 ,1-difluoropropyl or 1 ,2-difluoropropyl.
Where the heterocycle formed by R1 and R2 is substituted two fold or higher, the substituents may be on the same or different in-ring atoms.
R1 and R2 preferably represent, independent from each other, Ci-C4 alkyl or benzyl, optionally substituted by Ci-C4 alkoxy or halogen.
The above mentioned general or preferred radical definitions apply both to the end products of the formulae (I) , (II), (III) and (IV) and also, correspondingly, to the starting materials or intermediates required in each case for the preparation. These radical definitions can be combined with one another at will, i.e. including combinations between the given preferred ranges. Further, individual definitions may not apply.
Preference according to the invention is given to compounds of the formulae (I) , (II), (III) and (IV) which contain a combination of the meanings, mentioned above as being preferred.
Particular preference according to the invention is given to compounds of the formulae (I) , (II), (III) and (IV)which contain a combination of the meanings listed above as being particularly preferred.
Very particular preference according to the invention is given to the compounds of the formula (I) , (II), (III) and (IV) which contain a combination of the meanings listed above as being very particularly preferred.
Preferred are compounds of formulae (I) , (II) and (III) wherein R2 represents an unsubstituted or substituted heterocycle.
Particular preferred are compounds of formulae (Ha to Hd) as shown below:
Figure imgf000009_0001
wherein the substituents have the meaning given in this specification.
Figure imgf000010_0001
wherein the substituents have the meaning given in this specification.
Figure imgf000010_0002
wherein the substituents have the meaning given in this specification.
Figure imgf000010_0003
wherein R4 represents C1-C4BIkVl, preferably methyl and the other substituents have the meaning given in this specification.
Further preferred compounds of the present invention have the formulae (Ilia to IUd) as shown below:
Figure imgf000010_0004
wherein all of the substituents have the meaning given in this specification.
Figure imgf000010_0005
wherein the substituents have the meaning given in this specification.
Figure imgf000010_0006
(HIc) wherein the substituents have the meaning given in this specification.
Figure imgf000011_0001
wherein R4 represents halogen; C1-C4BIkVl, preferably methyl and the other substituents have the meaning given in this specification.
54
Where Q1 V and W are all CR , a preferred compound has a formula of (Ia):
Figure imgf000011_0002
wherein R4 represents C^C^Ikyl; hal looggeeni , preferably chloro and the other substituents have the meaning given in this specification, including the preferences mentioned herein.
A particularly preferred class of compounds have the formulae (IV):
Figure imgf000011_0003
wherein the substituents have the meaning given in this specification, including the preferences mentioned herein.
In one class of compounds having the formula (IV), R1 and R2 form together with the Nitrogen atom to which they are attached very particularly preferably represent a heterocycle, as described herein. In particular, the heterocycle is unsubstituted, a single or twofold substituted.
In another class of compounds having the formula (IV), R3 is preferably halogen, e.g. chloro.
In a further class of compounds having the formula (IV), R4 is preferably alkyl, e.g. methyl. In a further aspect, the invention provides process for the production of the compounds of formulae (I), (II), (III) and (IV) and their salts.
A first process, wherein Z represents NH or O, comprises the step of reacting a compound of formula (ii)
Figure imgf000012_0001
wherein R1 and R2 are as defined above, LG represents a leaving group such as Chlorine, Fluorine, methoxy, preferably chlorine, with a compound of formula (iii)
Figure imgf000012_0002
wherein Q, V, W is as defined above and Z represents NH or O, optionally in the presence of a reaction auxiliary,
and recovering the resulting compound in free base or acid addition salt form.
Such a process can be effected according to conventional methods, e.g. by aromatic nucleophilic substitution under acidic conditions as described in example 1. Optionally, the reaction is carried out under basic conditions in the presence or absence of a transition metal catalyst, e.g. by using for example potassium tert.-butoxide as base and palladium(ll) acetate / BINAP catalyst as described in example 2.
Alternatively compounds of the invention, e.g. of formula (I), can be prepared by coupling an amine of formula (iv)
R2 (iv) wherein R1 and R2 are defined as above and a carboxylic acid of formula (v)
Figure imgf000013_0001
Q, V, W, Y1X and Z are defined as above.
Such a process can be performed by transforming acid (v) into an acyl halide (e.g. by thionyl chloride) which is then reacted with the desired amine (iv) to give (I) as outlined in example 4. Alternatively, acid (v) can be activated by a peptide coupling agent (e.g. HATU) and then converted to (I) by addition of an amine (iv) as shown in example 5.
Starting materials of formula (ii), (iii), (iv) and (v) are known or obtainable by known methods.
A further process for making compounds of the present invention, wherein Z represents CH2, comprises the step of reacting a compound of formula (ii)
Figure imgf000013_0002
wherein R1 and R2 are as defined above, LG represents a leaving group such as Chlorine, Fluorine, methoxy, preferably chlorine, with a compound of formula (vi)
Figure imgf000013_0003
wherein Q, V, W is as defined above, optionally in the presence of a reaction auxiliary, such as a Zn / Ni(II) catalyst, e.g. Zn / NiCI2(bisphosphine),
and recovering the resulting compound in free base or acid addition salt form.
Starting materials of formula (ii) and (iv) are known or obtainable by known methods.
Compounds of the invention, e.g. of formula (II), are e.g. available by a process comprising the step of reacting a compound of formula (vii)
Figure imgf000014_0001
wherein X, Y and LG are as defined above with a compound of formula (iv)
R1R2NH (iv) wherein R1 and R2 are as defined above.
The starting materials of formula (vii) and (iv) are known or obtainable according to known methods. Instead of chlorine derivative (vi) the free acid in connection with an activating agent may be used. Such amid- formation reactions are known to the skilled person.
The following considerations apply to the individual reaction steps described above:
a) One or more functional groups, for example carboxy, hydroxy, amino, or mercapto, may need to be protected in the starting materials by protecting groups. The protecting groups employed may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products. The specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned hereinabove and hereinafter. The protection of such functional groups by such protecting groups, the protecting groups themselves, and their removal reactions are described for example in standard reference works, such as J. F. W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in T. W. Greene, "Protective Groups in Organic Synthesis", Wiley, New York 1981 , in "The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981 , in "Methoden der organischen Chemie" (Methods of organic chemistry), Houben Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart 1974, in H. -D. Jakubke and H. Jescheit, "Aminosauren, Peptide, Proteine" (Amino acids, peptides, proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and in Jochen Lehmann, "Chemie der Kohlenhydrate: Monosaccharide und Derivate" (Chemistry of carbohydrates: monosaccharides and derivatives), Georg Thieme Verlag, Stuttgart 1974. b) Acid addition salts may be produced from the free bases in known manner, and vice- versa. Compounds of formulae (I), (II), (III) and (IV) in optically pure form can be obtained from the corresponding racemates according to well-known procedures, e.g. HPLC with chiral matrix. Alternatively, optically pure starting materials can be used.
c) Stereoisomeric mixtures, e.g. mixtures of diastereomers, can be separated into their corresponding isomers in a manner known per se by means of suitable separation methods. Diastereomeric mixtures for example may be separated into their individual diastereomers by means of fractionated crystallization, chromatography, solvent distribution, and similar procedures. This separation may take place either at the level of a starting compound or in a compound of formula I itself. Enantiomers may be separated through the formation of diastereomeric salts, for example by salt formation with an enantiomer-pure chiral acid, or by means of chromatography, for example by HPLC, using chromatographic substrates with chiral ligands.
d) Suitable diluents for carrying out the above- described are especially inert organic solvents. These include, in particular, aliphatic, alicyclic or aromatic, optionally halogenated hydrocarbons, such as, for example, benzine, benzene, toluene, xylene, chlorobenzene, dichlorobenzene, petroleum ether, hexane, cyclohexane, dichloromethane, chloroform, carbon tetrachloride; ethers, such as diethyl ether, diisopropyl ether, dioxane, tetrahydrofuran or ethylene glycol dimethyl ether or ethylene glycol diethyl ether; ketones, such as acetone, butanone or methyl isobutyl ketone; nitriles, such as acetonitrile propionitrile or butyronitrile; amides, such as N.N-dimethylformamide, N1N- dimethylacetamide, N-methyl-formanilide, N-methyl-pyrrolidone or hexamethylphosphoric triamide; esters, such as methyl acetate or ethyl acetate, sulphoxides, such as dimethyl sulphoxide, alcohols, such as methanol, ethanol, n- or i-propanol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, diethyelene glycol monomethyl ether, diethylene glycol monoethyl ether. Further, mixtures of diluents may be employed. Depending on the starting materials, reaction conditions and auxiliaries, water or diluents constaining water may be suitable. It is also possible to use one a starting material as diluent simultaneously.
e) Reaction temperatures can be varied within a relatively wide range. In general, the processes are carried out at temperatures between 00C and 1500C, preferably between 100C and 1200C. Deprotonation reactions can be varied within a relatively wide range. In general, the processes are carried out at temperatures between -150°C and +50°C, preferably between -75°C and 0°C.
f) The reactions are generally carried out under atmospheric pressure. However, it is also possible to carry out the processes according to the invention under elevated or reduced pressure - in general between 0.1 bar and 10 bar.
g) Starting materials are generally employed in approximately equimolar amounts. However, it is also possible to use a relatively large excess of one of the components. The reaction is generally carried out in a suitable diluent in the presence of a reaction auxiliary, and the reaction mixture is generally stirred at the required temperature for a number of hours.
h) Work-up is carried out by customary methods (cf. the Preparation Examples).
i) A compound of formulae (I), (II), (III) and (IV) obtained according to the above described processes can be converted into another compound formulae (I), (II), (III) and (IV) according to conventional methods.
Compounds of formulae (I), (II), (III) and (IV) and their pharmaceutically acceptable acid addition salts, hereinafter referred to as agents of the invention, exhibit valuable pharmacological properties and are therefore useful as pharmaceuticals.
In particular, the agents of the invention exhibit a marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs). This can be determined in vitro for example at recombinant human metabotropic glutamate receptors, especially PLC-coupled subtypes thereof such as mGluR5, using different procedures like, for example, measurement of the inhibition of the agonist induced elevation of intracellular Ca2+ concentration in accordance with L. P. Daggett et al., Neuropharm. Vol. 34, pages 871-886 (1995), P. J. Flor et al., J. Neurochem. Vol. 67, pages 58-63 (1996) or by determination to what extent the agonist induced elevation of the inositol phosphate turnover is inhibited as described by T. Knoepfel et al., Eur. J. Pharmacol. Vol. 288, pages 389-392
(1994), L. P. Daggett et al., Neuropharm. Vol. 67, pages 58-63 (1996) and references cited therein. Isolation and expression of human mGluR subtypes are described in US-Patent No. 5,521,297. Selected agents of the invention show IC50 values for the inhibition of the agonist (e.g. glutamate or quisqualate) induced elevation of intracellular Ca2+ concentration or the agonist (e.g. glutamate or quisqualate) induced inositol phosphate turnover, measured in recombinant cells expressing hmGluR5a of about 1nM to about 50 μM.
The agents of the invention are therefore useful in the treatment of disorders associated with irregularities of the glutamatergic signal transmission, and of nervous system disorders mediated full or in part by mGluR5.
The agents of the invention are therefore useful in the prevention, treatment or delay of progression of disorders associated with irregularities of the glutamatergic signal transmission, of the gastro-intestinal and urinary tract and of nervous system disorders mediated full or in part by mGluR5.
Disorders associated with irregularities of the glutamatergic signal transmission are for example epileptogenesis including neuronal protection after status epilepticus, cerebral ischemias, especially acute ischemias, ischemic diseases of the eye, muscle spasms such as local or general spasticity, skin disorders, obesity disorders and, in particular, convulsions or pain.
Disorders of the gastro-intestinal tract include Gastro-Esophageal Reflux Disease (GERD), Functional Gastro-intestinal Disorders and Post-operative Ileus.
Functional Gastro-intestinal Disorders (FGIDs) are defined as chronic or recurrent conditions associated with abdominal symptoms without organic cause using conventional diagnostic measures. A cardinal symptom present in many FGIDs is visceral pain and/or discomfort. FGIDs include functional dyspepsia (FD), functional heartburn (a subset of GERD), irritable bowel syndrome (IBS), functional bloating, functional diarrhea, chronic constipation, functional disturbancies of the biliary tract as well as other conditions according to Gut 1999; Vol. 45 Suppl. II.
Post-operative Ileus is defined as failure of aboral passage of intestinal contents due to transient impairment of Gl motility following abdominal surgery.
Disorders of the Urinary Tract comprise conditions associated with functional disturbancies and/or discomfort/pain of the urinary tract. Examples of disorders of the urinary tract include but are not limited to incontinence, benign prostatic hyperplasia, prostatitis, detrusor hyperreflexia, outlet obstruction, urinary frequency, nocturia, urinary urgency, overactive bladder (OAB), pelvic hypersensitivity, urge incontinence, urethritis, prostatodynia, cystitis, idiopathic bladder hypersensitivity and the like. OAB is a syndrome characterized by urgency, with or without urinary incontinence, and usually with increased voiding frequency and nocturia.
Nervous system disorders mediated full or in part by mGluR5 are for example acute, traumatic and chronic degenerative processes of the nervous system, such as Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis and fragile X syndrome, substance-related disorders, psychiatric diseases such as schizophrenia, affective and anxiety disorders, attention deficit disorders and cognitive dysfunction associated with these and other CNS disorders. Substance-related disorders include substance abuse, substance dependence and substance withdrawal disorders. Anxiety disorders includes panic disorder, social and specific phobias, anxiety, obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD) and generalized anxiety disorder (GAD). Affective disorders include depressive (major depression, dysthymia, depressive disorders NOS) and bipolar disorders (bipolar I and Il disorders). Cognitive dysfunction associated with these and other CNS disorders include deficits and abnormalities in attention and vigilance, executive functions and memory (for instance working memory and episodic memory). Other disorders which are mediated fully or in part are pain and itch.
A further disorder is migraine.
The usefulness of the agents of the invention in the treatment of the above-mentioned disorders can be confirmed in a range of standard tests including those indicated below:
Activity of the agents of the invention in anxiety can be demonstrated in standard models such as the stress-induced hyperthermia in mice [cf. A. Lecci et al., Psychopharmacol. 101 , 255-261]. At doses of about 0.1 to about 30 mg/kg p.o., selected agents of the invention reverse the stress-induced hyperthermia. At doses of about 4 to about 50 mg/kg p.o., selected agents of the invention show reversal of Freund complete adjuvant (FCA) induced hyperalgesia [cf. J. Donnerer et al., Neuroscience 49, 693-698 (1992) and CJ. Woolf, Neuroscience 62, 327-331 (1994)].
Activity of the agents of the invention in GERD can be demonstrated in standard models such as the gastric distension-induced transient lower esophageal sphincter relaxations (TLESRs) in dogs. At doses of about 0.03 to about 10 mg/kg p.o., selected agents of the invention reduce the occurrence of TLESRs.
Activity of the agents of the invention in functional dyspepsia can be demonstrated a model of fasted gastric tone and gastric accommodation to meal in dogs. At doses of about 0.03 to about 10 mg/kg p.o., selected agents of the invention increase the gastric volume in fasting conditions indicative of a reduced gastric tone.
Activity of the agents of the invention in visceral hyperalgesia can be demonstrated in standard rat models according to modified methods by Tarrerias, A. et al., Pain (2002) 100: 91-97, Schwetz, I. et al., Am. J. Physiol. (2005) 286: G683-G691 , of La, J. et al., World J. Gastroenterol. (2003) 9: 2791-2795. At doses of about 0.03 to about 30 mg/kg p.o., selected agents of the invention reduce the exaggerated abdominal striated muscle contractions, indicative of a visceral antinociceptive activity.
Activity of the agents of the invention in visceral sensation/pain of the urinary bladder can be demonstrated in a standard mouse model according to a modified method by Ness TJ and Elhefni H. J Urol. (2004) 171 :1704-8. At doses of about 0.3 to about 30 mg/kg p.o., selected agents of the invention reduce the EMG (visceromotor) response, indicative of a visceral antinociceptive and /or hyposensitivity.
Activity of the agents of the invention in overactive bladder and urge incontinence can be demonstrated in standard cystometry models in rats according to modified method by Tagaki-Matzumoto et al J. Pharmacol. Sci. (2004) 95 : 458-465. At doses of about 0.03 to about 10 mg/kg p.o., selected agents of the invention increased threshold volumes eliciting bladder contractions indicative of therapeutic potential in conditions with bladder dysfunctions. For all the above mentioned indications, the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.05 to about 100 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 5 to 1500 mg, preferably about 10 to about 1000 mg of the compound conveniently administered in divided doses up to 4 times a day or in sustained release form.
In accordance with the foregoing, the present invention also provides in a further aspect an agent of the invention for use as a pharmaceutical, e.g. in the treatment of disorders associated with irregularities of the glutamatergic signal transmission, and of nervous system disorders mediated full or in part by mGluR5.
The invention also provides the use of an agent of the invention, in the treatment of disorders associated with irregularities of the glutamatergic signal transmission, and of nervous system disorders mediated full or in part by mGluR5.
In a further aspect, the invention provides the use of compounds of formula (I) as modulators of metabotropic Glutamate Receptors, Subtype 5 ("mGluR5 - Modulators").
Furthermore the invention provides the use of an agent of the invention for the manufacture of a pharmaceutical composition designed for the treatment of disorders associated with irregularities of the glutamatergic signal transmission, and of nervous system disorders mediated full or in part by mGluR5.
In a further aspect the invention relates to a method of treating disorders mediated full or in part by mGluR5, which method comprises administering to a warm-blooded organism in need of such treatment a therapeutically effective amount of an agent of the invention.
Moreover the invention relates to a pharmaceutical composition comprising an agent of the invention in association with one or more pharmaceutical carrier or one or more pharmaceutically acceptable diluent. The pharmaceutical compositions according to the invention are compositions for enteral, such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (human beings and animals) that comprise an effective dose of the pharmacological active ingredient alone or together with a significant amount of a pharmaceutically acceptable carrier. The dose of the active ingredient depends on the species of warm-blooded animal, body weight, age and individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.
The pharmaceutical compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient. Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragees, tablets or capsules.
The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes.
Preferred are the compounds according to the examples.
Further, properly isotope-labeled agents of the invention exhibit valuable properties as histopathological labeling agents, imaging agents and/or biomarkers, hereinafter "markers", for the selective labeling of the metabotropic glutamate receptor subtype 5 (mGlu5 receptor). More particularly the agents of the invention are useful as markers for labeling the central and peripheral mGlu5 receptors in vitro or in vivo. In particular, compounds of the invention which are properly isotopically labeled are useful as PET markers. Such PET markers are labeled with one or more atoms selected from the group consisting of 11C, 13N, 150, 18F.
The agents of the invention are therefore useful, for instance, for determining the levels of receptor occupancy of a drug acting at the mGlu5 receptor, or diagnostic purposes for diseases resulting from an imbalance or dysfunction of mGluδ receptors, and for monitoring the effectiveness of pharmacotherapies of such diseases.
In accordance with the above, the present invention provides an agent of the invention for use as a marker for neuroimaging. In a further aspect, the present invention provides a composition for labeling brain and peripheral nervous system structures involving mGlu5 receptors in vivo and in vitro comprising an agent of the invention.
In still a further aspect, the present invention provides a method for labeling brain and peripheral nervous system structures involving mGlu5 receptors in vitro or in vivo, which comprises contacting brain tissue with an agent of the invention.
The method of the invention may comprise a further step aimed at determining whether the agent of the invention labeled the target structure. Said further step may be effected by observing the target structure using positron emission tomography (PET) or single photon emission computed tomography (SPECT), or any device allowing detection of radioactive radiations.
The following non-limiting Examples illustrate the invention. A list of Abbreviations used is given below.
AcOH acetic acid
BOC tert-butoxycarbonyl n-BuLi n-butyl lithium
DMF N.N'-dimethylformamide
EDC 1 -ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride
HOBt hydroxybenzotriazole
AcN acetonitrile BINAP (2,2'-bis(diphenylphosphino)-1 ,1'-binaphthyl
DAST (Diethylamino)sulfur trifluoride
DCE 1,2-dichloroethane
DCM dichloromethane
DIPEA N,N-diisopropylethylamine DMA N,N-dimethylacetamide
DMAP 4-N,N-dimethylaminopyridine
DME 1 ,2-dimethoxyethane
DMSO dimethylsulfoxide
EtOAc ethylacetate ESI electrospray ionization h hours
HCI hydrochloric acid
HATU N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridine-1-ylmethylene]-Λ/-methyl- methanaminium hexafluorophosphate Λf'-oxide
HMPA hexamethylphosphoramide
HPLC high pressure liquid chromatography min minutes
Mp melting point
MS mass spectroscopy
MTBE methyl-terf.-butylether
Rf retention factor (Thin Layer Chromatography) rt room temperature tR retention time
TFA trifluoroacetic acid
THF tetrahydrofuran
HPLC specificity
System 1 : System 1: Performed on a Waters system equipped with a CTC Analytics HTS PAL autosampler, 515 pumps, and a 996 DAD detector operating at 210 nm. Column: CC70/3 Nucleosil 100-3 Ci8 (3 μ, 70 x 3 mm, Macherey-Nagel, order # 721791.30), temperature: 45°C, flow: 1.2 mL min"1. Eluents: A: Water + 0.2% H3PO4 (85%, (Merck 100552) + 2% Me4NOH, (10%, Merck 108123), B: Acetonitrile + 20% water + 0.1% H3PO4 (85%) + 1% Me4NOH (10%). Gradient: 0% B to 95% B within 6.6 min., then 95% B 4.4 min. System 2: Gilson 331 pumps coupled to a Gilson UV/VIS 152 detector and a Finnigan AQA spectrometer (ESI), a 50 μL loop injection valve and a Waters XTerra MS C18 3.5 μm 4.6x50 mm column running a gradient from 5% to 90% acetonitrile containing 0.05% TFA. System 3: Agilent 1100 Series, LC-MSD and a Agilent Zorbax SB-C18 3x30mm 1.8μm Column running a gradient Water + 0.05% TFA / Acetonitrile + 0.05% TFA from 100/0 to 0/100 over 3.25' - 0/100 over 0.75' - 0/100 to 90/10 over 0.25' with a flux of 0.7 ml/min, 35°C.
System 4: Agilent 1100 Series, LC-MSD and a Agilent Zorbax SB-C 18 3x30mm 1.8μm Column running a gradient Water + 0.05% TFA / Acetonitrile + 0.05% TFA from 90/10 to 0/100 over 3.25' - 0/100 over 0.75' - 0/100 to 70/30 over 0.25' with a flux of 0.7 ml/min, 35°C. System 5: Agilent 1100 Series, LC-MSD and a Agilent Zorbax SB-C18 3x30mm 1.8μm Column running a gradient Water + 0.05% TFA / Acetonitrile + 0.05% TFA from 70/30 to 0/100 over 3.251 - 0/100 over 0.75' - 0/100 to 60/40 over 0.25' with a flux of 0.7 ml/min, 35°C. System 6: Agilent 1100 Series, LC-MSD and a Agilent Zorbax SB-C18 3x30mm 1.8μm
Column running a gradient Water + 0.05% TFA / Acetonitrile + 0.05% TFA from 30/70 to 0/100 over 3.25' - 0/100 over 0.75' - 0/100 to 90/10 over 0.25' with a flux of 0.7 ml/min, 350C.
Example 1.1 : 6-(4-Chloro-phenylamino)-N, N-diethyl-nicotinamide hydrochloride 6-Chloro-N,N-diethyl-nicotinamide (100 mg, 0.47 mmol) and 4-chloroaniline (184 mg, 1.41 mmol) are suspended in a mixture of glacial acetic acid (0.6 mL) and water (1.4 mL). The reaction mixture is heated in a sealed 3 mL-vial to 100 0C over night. After reaching room temperature the reaction mixture is poured onto MTBE (30 mL) and extracted with 2M HCI (3x 5 mL). The combined acidic extracts are made alkaline by addition of 2M NaOH (10 mL) extracted with MTBE (3x 15 mL). The combined organic extracts are dried (Na2SO4) and evaporated to dryness to. The residue is purified by flash-chromatography. To the combined product containing fractions is added 4M HCI in dioxane (0.25 mL) followed by evaporation. The residue is triturated with ether, filtered off, washed with cold ether and vacuum dried at 45 0C to give the title compound as colorless crystals (90 mg, 56%). TLC: Rf = 0.16 (MTBE), HPLC: tR = 6.0 min, (system 1); ESI+ MS: m/z = 304.5 (MH+).
The starting material can be prepared as described hereafter:
6-Chloro-N,N-diethyl-nicotinamide
Under Ar, chloronicotinoyl chloride (4 g, 22 mmol) is suspended in DCM (40 mL). The reaction flask is placed in an ice bath and a solution of diethylamide (2.31 mL, 22 mmol) and triethylamine (3.90 mL, 27.8 mmol) in DCM (40 mL) is added within 45 min keeping the internal temperature below 5 0C. The ice bath is removed and the reaction mixture is stirred for further 30 min. The solution is washed (1x water (40 mL), 1x 1M Na2CO3 (40 mL), 1x water (40 mL)), dried over Na2SO4 and evaporated to dryness to afford a reddish orange oil (4.50 g, 95%) which can be used without further purification. Following the same procedure, the following compounds can be prepared:
Example 1.2: N.N-Diethyl-β-p-tolylamino-nicotinamide hydrochloride
Yellowish lyophilisate, TLC: Rf = 0.22 (MTBE), HPLC: tR = 5.5 min, (system 1); ESI+ MS: m/z = 284.6 (MH+).
Example 1.3: N, N-Diethyl-6-(4-methoxy-phenylamino)-nicotinamide hydrochloride
Light gray crystals, TLC: Rf = 0.14 (MTBE), HPLC: tR = 4.6 min, (system 1); ESI+ MS: m/z = 300.6 (MH+).
Example 1.4: 6-(4-Chloro-phenylamino)-N,N-bis-(2-methoxy-ethyl)-nicotinamide hydrochloride
Yellowish lyophilisate, TLC: R, = 0.10 (MTBE), HPLC: tR = 5.6 min, (system 1); ESI+ MS: m/z = 364.5 (MH+).
Example 1.5: f6-(4-Chloro-3-fluoro-Dhenvlamino)-Dvridin-3-vll-DiDeridin-1-vl-methanone Colorless crystals, HPLC: tR = 6.6 min, (system 1); ESI+ MS: m/z = 334.5 (MH+).
Example 1.6: [6-(4-Bromo-phenylamino)-Dvridin-3-vl]-piperidin-1-vl-methanone Colorless crystals, TLC: R, = 0.31 (MTBE-ETOAC 9:1 ), HPLC: tR = 6.3 min, (system 1); ESI+ MS: m/z = 360.6 (MH+).
Example 1.7: 4-[5-(Piperidine-1-carbonvl)-pyridin-2-vlamino1-benzonitrile
Colorless crystals, TLC: Rf = 0.14 (MTBE), HPLC: tR = 5.7 min, (system 1 ); ESI+ MS: m/z = 307.6 (MH+).
Example 1.8: Piperidin- 1 -yl-[6-(4-trifluoromethoxy-phenylamino) -pyridin-3-yl]-methanone Colorless crystals, TLC: R, = 0.29 (DCM-ETOAC 7:3), HPLC: tR = 6.6 min, (system 1); ESI+ MS: m/z = 366.7 (MH+).
Example 1.9: !6-(4-Chloro-Dhenvlamino)-Dvridin-3-vll-(2-methvl-DiDeπdin-1-vl)-methanone hydrochloride
TLC: Rf = 0.23 (MTBE), HPLC: tR = 6.5 min, (system 1); ESI+ MS: m/z = 330.5 (MH+).
Example 1.10: (2-Methvl-piDeridin-1-vl)-(6-D-tolvlamino-Dvridin-3-yl)-methanone
Beige crystals, TLC: Rf = 0.24 (MTBE), HPLC: tR = 6.0 min, (system 1); ESI+ MS: m/z = 310.5 (MH+).
Example 1.11: f6-(4-Methoxv-Dhenvlamino)-Dvndin-3-vlJ-(2-methyl-piDeridin-1-vl)-methanone hydrochloride
Purple crystals, TLC: Rf = 0.27 (MTBE), HPLC: tR = 5.4 min, (system 1); ES!+ MS: m/z = 326.5 (MH+).
Example 1.12: rac-[6-(4-Chloro-Dhenvlamino)-Dvridin-3-vl]-(3-methyl-DiDeridin-1-vl)- methanone
Colorless crystals, TLC: R, = 0.25 (MTBE), HPLC: tR = 6.6 min, (system 1 ); ESI+ MS: m/z = 330.5 (MH+).
Using either S-3-methylpiperidine or R-3-methylpiperidine as starting material the pure enantiomers could be prepared:
Example 1.12a: f6-(4-Chloro-Dhenvlamino)-Dvridin-3-vl1-(S-3-methvl-piDeridin-1-vl)- methanone
Colorless crystals. TLC: Rf, = 0.22 (MTBE), HPLC: tR = 6.7 min, (system 1); ESI+ MS: m/z 330.1 (MH+). Example 1.12b: f6-(4-Chloro-phenvlamino)-pvridin-3-vl]-(R-3-methyl-piperidin-1-vl)- methanone
Beige crystals, HPLC: tR = 6.7 min, (system 1); ESI+ MS: m/z = 330.2 (MH+).
Example 1.13: 3-Methyl-piperidin- 1 -yl)-(6-p-tolylamino-pyridin-3-yl)-methanone Pink lyophilisate, HPLC: tR = 6.2 min, (system 1); ESI+ MS: m/z = 310.5 (MH+).
Example 1.14: f6-(4-Methoxv-phenvlamino)-pvridin-3-vll-(3-methyl-piperidin-1-vl)-methanone hydrochloride Brown crystals, HPLC: tR = 5.6 min, (system 1); ESI+ MS: m/z = 326.5 (MH+).
Example 1.15: (3-Methvl-piperidin-1-vl)-(6-phenvlamino-pyridin-3-vl)-methanone hydrochloride
Colorless crystals, TLC: Rf = 0.26 (MTBE), HPLC: tR = 5.8 min, (system 1 ); ESI+ MS: m/z = 296.5 (MH+).
Example 1.16: f6-(3-Chloro-phenvlamino)-pvridin-3-vll-(3-methvl-piperidin-1-vl)-methanone hydrochloride
TLC: Rf = 0.27 (MTBE), HPLC: tR = 6.6 min, (system 1 ); ESI+ MS: m/z = 330.5 (MH+).
Example 1.17: [6-(4-Chloro-phenvlamino)-pvridin-3-vll-morpholin-4-yl-methanone hydrochloride
Yellowish crystals, TLC: Rf = 0.38 (MTBE-MeOH 9:1), HPLC: tR = 5.5 min, (system 1); ESI+ MS: m/z = 318.5 (MH+).
Example 1.18: [6-(4-Methoxv-phenvlamino)-pyridin-3-vll-morpholin-4-vl-methanone hydrochloride
Greenish solid, TLC: R, = 0.35 (MTBE-MeOH 9:1 ), HPLC: tR = 4.0 min, (system 1); ESI+ MS: m/z = 314.5 (MH+). Example 1.19: cis-[6-(4-Chloro-phenvlamino)-Dvridin-3-vll-(2.6-dimethvl-morpholin-4-vl)- methanone hydrochloride
Colorless crystals, TLC: R, = 0.13 (MTBE), HPLC: tR = 6.1 min, (system 1); ESI+ MS: m/z = 346.5 (MH+).
Example 1.20: (cis-2.6-Dimethvl-morpholin-4-yl)-(6-p-tolvlamino-Dvridin-3-vl)-methanone hydrochloride
Beige crystals, TLC: Rf = 0.24 (MTBE), HPLC: tR = 5.4 min, (system 1); ESI+ MS: m/z = 326.6 (MH+).
Example 1.21 : (cis-2,6-Dimethvl-morpholin-4-vl)-[6-(4-methoxv-Dhenvlamino)-pvridin-3-vlh methanone hydrochloride
Purple crystals, TLC: Rf = 0.16 (MTBE), HPLC: tR = 4.9 min, (system 1); ESI+ MS: m/z = 342.5 (MH+).
Example 2.1 : f6-(5-Chloro-Dvridin-2-ylamino)-Dvridin-3-vl]-piperidin-1-vl-methanone
A solution of palladium(ll) acetate (2 mg, 9 μmol) and BINAP (5.6 mg, 9 μmol) in dry and degassed toluene (1.5 mL) is stirred for 10 min under Ar. Then, the clear yellow solution obtained is added to a degassed suspension of (6-chloro-pyridin-3-yl)-piperidin-1-yl- methanone (100 mg, 0.45 mmol, prepared according to the general procedure stated in example 1.1 ), 2-amino-5-chloropyridine (70 mg, 0.53 mmol), and KOfBu (257 mg, 2.22 mmol) in dry toluene. The reaction mixture is stirred for 5 h in a sealed 5 mL-vial. After reaching room temperature the mixture is poured into MTBE (30 mL), washed (3x H2O (20 mL)), dried over Na2SO4 and evaporated to give a turbid oil. Crystallization from Et2O affords the title compound as beige crystals (87 mg, 62%), HPLC: tR = 4.8 min, (system 1 ); ESI+ MS: m/z = 317.6 (MH+).
Following the same procedure, the following compounds can be prepared: Example 2.2: Azepan- 1 -yl-[6-(pyridin-3-ylamino) -pyridin-3-yl]-methanone
Yellowish lyophilisate, TLC: R, = 0.28 (MTBE-MeOH 85:15), HPLC: tR = 4.2 min, (system 1); ESI+ MS: m/z = 297.2 (MH+).
Example 2.3: [6-(3, 4-Difluoro-phenylamino)-pyridin-3-yl]-piperidin-1-yl-methanone Colorless crystals, HPLC: tR = 6.1 min, (system 1); ESI+ MS: m/z = 318.6 (MH+).
Example 2.4: rac-(2-Aza-bicyclo[2.2.1]hept-2-y\)-[5-ch\oro-6-(4-chloro-pheny\aπ\m' ό)-pyr\dm' - 3-yl]-methanone Beige powder, HPLC: tR = 6.9 min, (system 1 ); ESI+ MS: m/z = 364.0 (MH+).
Example 2.5: f5-Chloro-6-(4-chloro-Dhenvlamino)-Dvridin-3-yll-thiomorDholin-4-vl-methanone Beige powder, HPLC: tR = 6.6 min, (system 1 ); ESI+ MS: m/z = 370.0 (MH+).
Example 2.6: rac-[5-Chloro-6-(6-methoxy-pyridin-3-ylamino)-pyridin-3-yl]'(3-methyl-piperidin- 1-yl)-methanone
Beige lyophilisate, TLC: Rf = 0.49 (MTBE), HPLC: tR = 6.2 min (system 1 ); ESI+ MS: m/z = 361.1 (MH+).
Example 2.7: AzeDan-1-vl-I5-ch1oro-6-(6-methoxv-Dvridin-3-vlamino)-Dvridin-3-vll-rnethanone
Beige lyophilisate, TLC: Rf = 0.32 (MTBE), HPLC: tR = 6.0 min (system 1 ); ESI+ MS: m/z = 361.1 (MH+).
Example 2.8: [S-Chloro-β-fβ-methoxy-pyridin-S-ylaminoJ-pyridin-S-ylJ-piperidin- 1 -yl- methanone
Colorless lyophilisate, TLC: Rf = 0.36 (MTBE), HPLC: tR = 5.9 min (system 1 ); ESI+ MS: m/z = 347.0 (MH+). Example 2.9: f5-Chloro-6-(6-ethoxv-pyridin-3-vlamino)-pvridin-3'Vll-piperidin-1-vl-methanone Colorless lyophilisate, TLC: Rf = 0.23 (EtOAc/hexanes 1:1), LC/MS: m/z = 361 (MH+).
Example 2.10: rac-fδ-Chloro-β-fG-methyl-pyήdin-S-vlaminoi-pvhdin-d-vll-O-methvl-piperidin- 1 -yl)-methanone
Beige crystals, HPLC: tR = 4.7 min (system 1); ESI+ MS: m/z = 345.1 (MH+).
Using either S-3-methylpiperidine or R-3-methylpiperidine as starting material the pure enantiomers could be prepared:
Example 2.10a: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(S-3-methyl-piperidin- 1-yl)-methanone
Brown gum, HPLC: tR = 4.7 min (system 1); ESI+ MS. m/z = 345.1 (MH+)
Example 2.10b: fS-Chloro-β-fβ-methyl-pvridin-d-ylaminoi-pvήdm-S-vlMRS-methvl-piperidin- 1-yl)-methanone
Brown gum, HPLC: tR = 4.5 min (system 1); ESI+ MS. m/z = 345.1 (MH+)
Example 2.11 : [δ-Chloro-β-fβ-methyl-pvridin-S-vlaminoj-pvridin-S-vll-piperidin-i-yl- methanone Colorless crystals, HPLC: tR = 4.3 min (system 1); ESI+ MS: m/z = 331.1 (MH+).
Example 2.12: Azepan-1-yl-(5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-vn-methanone Colorless crystals, HPLC: tR = 4.3 min (system 1); ESI+ MS: m/z = 345.1 (MH+).
Example 2.13: rac-(2-Aza-bicyclo[2.2.1]hept-2-yl)-[5-chloro-6-(6-methyl-pyridin-3-ylamino)- pyridin-3-yl]-methanone
Beige powder, HPLC: tR = 4.1 min (system 1 ); ESI+ MS: m/z = 343.1 (MH+). Example 2.14: f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvπdin-3-vll-thiazolidin-3-vl- methanone
Beige powder, HPLC: tR = 4.1 min (system 1); ESI+ MS: m/z = 335.0 (MH+).
Example 2.15: [S-Chloro-β-fβ-methvl-pvridin-S-vlaminoj-pyridin-S-vlHhiomorpholin-^vl- methanone
Beige powder, HPLC: tR = 3.9 min (system 1); ESI+ MS: m/z = 349.0 (MH+).
Example 2.16: [5-Chloro-6-(2-methyl-pyήmidin-5-ylamino)-pyridin-3-yl]-(3-methyl-piperidin-1- yl)-methanone
Colorless crystals, HPLC: tR = 5.6 min (system 1); ESI+ MS: m/z = 346.1 (MH+).
Example 2.17: [5-Chloro-6-(2-methvl-pvrimidin-5-vlamino)-pyridin-3-vll-piperidin-1-vl- methanone
Colorless crystals, HPLC: tR = 5.1 min (system 1 ); ESI+ MS: m/z = 332.1 (MH+).
Example 2.18: Azepan-1-vl-[5-chloro-6-(2-methvl-pvrimidin-5-vlamino)-pyridin-3-vll- methanone Colorless crystals, HPLC: tR = 5.5 min (system 1 ); ESI+ MS: m/z = 346.1 (MH+).
Example 2.19: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(3-ethyl-piperidin-1-yl)- methanone
A mixture of (5,6-dichloro-pyridin-3-yl)-(3-ethyl-piperidin-1-yl)-methanone (300 mg, 1.04 mmol), 3-amino-6-methyl pyridine (171 mg, 1.57 mmol), Pd(OAc)2 (7 mg, 0.03 mmol), rac- BINAP (20 mg, 0.03 mmol) and potassium carbonate (723 mg, 5.2 mmol) in degassed toluene (10 mL) was stirred, under argon, at 800C for 3 hours. EtOAc was added and the organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to give a crude beige powder. The crude material was sonicated in pentane/Et2O and then filtered. After high-vacuum drying, [5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(3- ethyl-piperidin-1-yl)-methanone (100 mg, 27%) was obtained as a beige powder. (ES-MS: m/z 359.3/361.3 [M+H]\ tR 3.52 min (system 2)).
The starting material was prepared as described hereafter:
i) 3-ethyl piperidine
3-Ethyl pyridine (5.0 g, 46.7 mmol) was hydrogenated in AcOH (100 ml.) over PtO2 (500 mg) under 4 bar for 4 hours. The mixture was filtered through a pad of celite and washed with AcOH. The solvent was removed in vacuo and the residue was dissolved into water. The solution was basified by addition with 40% NaOH solution. The aqueous phase was extracted with Et2O. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford 3-ethyl piperidine (4.4 g, 83%) as a clear yellow oil.
ii) (5,6-Dichloro-pyridin-3-yl)-(3-ethyl-piperidin-1-yl)-methanone
A mixture of 5,6 dichloronicotinic acid (1 g, 5.2 mmol) in SOCI2 (6 mL) was stirred at 700C for 4 hours. The solvent was removed in vacuo to give a beige oil (1.05 g) corresponding to the acid chloride. This oil was solublised in DCM (15 mL) and at 0°C triethylamine (1.1 mL, 7.84 mmol) was added. Then, a solution of 3-ethyl piperidine (657 mg, 5.75 mmol) in DCM (5 mL) was added carefully drop-wise. At the end of the addition, the mixture was stirred at RT for 30 min. Water was added and the aqueous phase was extracted with DCM. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to (5,6- dichloro-pyridin-3-yl)-(3-ethyl-piperidin-1-yl)-methanone (1.2 g, 80%) as a yellow oil. (ES-MS: m/z 328.2/330.2 [M+CH3CN+ H]+, tR 5.48 min (system 2)).
Example 2.20: [5-Chloro-6-(6-methoxy-pyridin-3-ylamino)-pyridin-3-yl]-(3-ethyl-piperidin- 1 - yl)-methanone
A mixture of (5,6-dichloro-pyridin-3-yl)-(3-ethyl-piperidin-1-yl)-methanone (300 mg, 1.04 mmol), 5-amino-2-methoxy pyridine (201 mg, 1.57 mmol), Pd(OAc)2 (7 mg, 0.03 mmol), rac-
BINAP (20 mg, 0.03 mmol) and potassium carbonate (723 mg, 5.2 mmol) in degassed toluene (10 mL) was stirred, under argon, at 800C for 3 hours. EtOAc was added and the organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to give a crude beige powder. The crude material was purified by flash chromatography using EtOAc/Hexanes as eluent to afford [5-chloro-6-(6-methoxy-pyridin-3-ylamino)-pyridin- 3-yl]-(3-ethyl-piperidin-1-yl)-methanone (60 mg, 15%) as a beige powder. (ES-MS: m/z 375.3/375.5 [M+H]\ tR 5.21 min (system 2))
Example 2.21 : f5-Chloro-6-(4-chloro-phenvlamino)-pyridin-3-vll-(3-ethvl-piperidin-1-vl)- methanone
A mixture of (5,6-dichloro-pyridin-3-yl)-(3-ethyl-piperidin-1-yl)-methanone (300 mg, 1.04 mmol), 4-chloro aniline (206 mg, 1.57 mmol), Pd(OAc)2 (7 mg, 0.03 mmol), rac-BINAP (20 mg, 0.03 mmol) and potassium carbonate (723 mg, 5.2 mmol) in degassed toluene (10 mL) was stirred, under argon, at 800C for 3 hours. EtOAc was added and the organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to give a crude beige powder. The crude material was purified by flash chromatography using EtOAc/Hexanes as eluent to afford [5-chloro-6-(4-chloro-phenylamino)-pyridin-3-yl]-(3-ethyl- piperidin-1-yl)-methanone (150 mg, 38%) as a beige powder. (ES-MS: m/z 378.2/380.3 [M+H]\ tR 6.50 min (system 2))
Example 2.22: [5-Ch\oro-6-(Q-methy\-pynd\n-Z-y\ammo)-pyήdϊn-3-y\]-(3-propyl-p\peήdin- 1 -yl)- methanone
A mixture of (5,6-dichloro-pyridin-3-yl)-(3-propyl-piperidin-1-yl)-methanone (440 mg, 1.26 mmol), 3-amino-6-methyl pyridine (210 mg, 1.88 mmol), Pd(OAc)2 (8.6 mg, 0.03 mmol), rac- BINAP (24 mg, 0.03 mmol) and potassium carbonate (879 mg, 5.0 mmol) in degassed toluene (10 mL) was stirred, under argon, at 800C for 3 hours. EtOAc was added and the organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to give a crude beige powder. The crude material was purified by flash chromatography using EtOAc/Hexanes as eluent to afford [5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3- yl]-(3-propyl-piperidin-1-yl)-methanone (110 mg, 23%) as a beige powder. (ES-MS: m/z 373.3/375.3 [M+H]\ tR 4.52 min (system 2))
The starting material was prepared as described hereafter:
i) 3-propyl pyridine At 0°C, to a mixture of diisopropylamine (3.53 ml_, 24.7 mmol) in THF (35 ml_), BuLi (1.6 M in hexanes, 15.4 ml_, 25 mmol) was added drop-wise. After 30 min, HMPA (15.7 g, 24.7 mmol) was aded and the mixture was kept at 00C for 15 min. Then a solution of 3-methyl pyridine (2.3 g, 24.7 mmol) in THF (10 ml.) was added drop-wise. After 30 min, EtI (3.45 g, 24.7 mmol) in THF (10 mL) was added drop-wise and the mixture was then stirred at RT for 1 hour. The mixture was poured into 10% HCI. The aqueous phase was extracted with Et2O. The organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to afford a yellow oil (300 mg, 10%) which will be used without further purification.
ii) 3-propyl piperidine
3-propyl pyridine (300 mg, 2.48 mmol) was hydrogenated in AcOH (20 mL) over PtO2 (50 mg) under 4 bar for 16 hours. The mixture was filtered through a pad of celite and washed with AcOH. The solvent was removed in vacuo and the residue was dissolved into water. The solution was basified by addition with 40% NaOH solution. The aqueous phase was extracted with Et2O. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford 3-propyl piperidine (300 mg, 95%) as a clear yellow oil.
iii) (5,6-Dichloro-pyridin-3-yl)-(3-propyl-piperidin-1-yl)-methanone
5,6-Dichloro-nicotinoyl chloride (550 mg, 2.61 mmol) was solubilised in DCM (15 mL) and at 00C triethylamine (0.54 mL, 3.95 mmol) was added. Then, a solution of 3-propyl piperidine (369 mg, 2.87 mmol) in DCM (5 mL) was added carefully drop-wise. At the end of the addition, the mixture was stirred at RT for 30 min. Water was added and the aqueous phase was extracted with DCM. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford a beige-brown oil. This oil was sonicated in pentane to afford (5,6-dichloro-pyridin-3-yl)-(3-propyl-piperidin-1-yl)-methanone (440 mg, 48%) as a beige- brown solid.
Example 2.23: [δ-Chloro-β-fβ-trifluoromethvl-Dvridin-S-vlaminoϊ-Dvridin-S-vll-ffR^-ethvl- piperidin-1-yl)-methanone LC/MS: m/z = 413 (MH+); TLC: R, = 0.40 (DCM/MeOH 95:5).
Example 2.24: {5-Chloro-6-(6-methoxv-Dvridin-3-vlamino)-Dvridin-3-vll-((R)-2-ethvl-DiDeridin- 1-yl)-methanone
LC/MS: m/z = 375 (MH+); TLC: R, = 0.40 (DCM/MeOH 95:5). Example 3.1: rac-fi-Chloro-β-fβ-methyl-pyridin-S-yloxyj-pyridin-S-ylJ-β-methyl-piperidin- 1 - yl)-methanone
To a solution of rac-(5,6-dichloropyridin-3-yl)-(3-methyl-piperidin-1-yl)-methanone (50 mg, 0.18 mmol, prepared according to the procedure stated in example 1.1) and 4-chlorophenol
(23.5 mg, 0.18 mmol) in dry DMA (1 ml_) is added finely ground anhydrous K2CO3 (50.6 mg,
0.36 mmol). The suspension is microwave heated to 140 0C in a sealed 5 mL-vial for 45 min with stirring. Then, the reaction mixture is diluted with ethyl acetate (10 mL) and washed with brine (10 mL). The organic layer is dried (Na2SO4) and evaporated to dryness to give a brown oil. Purification by preparative HPLC afforded the title compound as colorless syrup
(40 mg, 60%), HPLC: tR = 7.1 min (system 1); ESI+ MS: m/z = 365.0 (MH+).
Following the same procedure, the following compounds can be prepared:
Example 3.2: [5-Chloro-6-(6-methyl-pyndin-3-yloxy)-pyndin-3-yl]-pipendin-1-yl-methanone Colorless syrup, HPLC: tR = 6.8 min (system 1); ESI+ MS: m/z = 351.0 (MH+).
Example 3.3: AzeDan-1-vl-[5-chloro-6-(6-methvl-pvridin-3-vloxv)-Dvridin-3-vll-methanone Colorless syrup, HPLC: tR = 7.0 min (system 1); ESI+ MS: m/z = 365.0 (MH+).
Example 4.1 : f6-(6-Methvl-Dvridin-3-vlamino)-pvridin-3-vll-piperidin-1-vl-methanone
To 6-(6-methyl-pyridin-3-ylamino)-nicotinic acid (210 mg, 0.92 mmol) is added thionyl chloride (2 mL). The colorless suspension is refluxed under argon for 20 min. After cooling the excess thionyl chloride is stripped off. The residue is redissolved in DCM (6 mL) and a solution of piperidine (0.11 mL, 1.10 mmol) and triethylamine (1.28 mL, 9.16 mmol) in DCM (2 mL) is quickly added. The yellow slightly turbid solution is stirred for 20 min at room temperature. Then, MTBE (60 mL) is added and the solution is extracted twice with water and brine. The organic layer is dried over Na2SO4 and evaporated to give a yellow foam. Flash chromatography (20 g silica gel, MeOH-MTBE gradient 2% -> 15% MeOH, flow 20 mL min"1) followed by crystallization from ether affords the title compound as colorless crystals (573 mg, 63%), TLC: R, = 0.18 (MTBE-MeOH 9:1), HPLC: tR = 3.8 min (system 1); ESI+ MS: m/z = 297.5 (MH+).
The starting material can be prepared as described hereafter:
D Methyl 6-(6-Methyl-pyridin-3-ylamino)-nicotinate
To 5-amino-2-methylpyridine (2.22 g, 20.56 mmol) and finely ground anhydrous K2CO3 (11.9 g, 85.2 mmol) is added dry toluene (30 mL) under argon. Then, a solution of palladium(ll) acetate (79 mg, 0.34 mmol) and BINAP (218 mg, 0.34 mmol) in dry toluene (10 mL) is added. The reaction mixture is placed in an oil bath (70 0C) and a solution of methyl 6- chloronicotinate (3.0 g, 17.1 mmol) in dry toluene (20 mL) is added dropwise within 30 min. After 1.5 h the oilbath is removed and the reaction flask is placed in an ice bath. After stirring for 15 min the product is filtered off. The filter cake is triturated three times with THF / MeOH 1:1 (100 mL). The combined extracts are evaporated to dryness to give a brown powder. Flash chromatography (gradient MTBE-MeOH 100:0 - MTBE-MeOH 85:15) followed by crystallization from ether gives the product as light pink crystals (1.86 g, 45%).
ii) 6-(6-Methyl-pyridin-3-ylamino)-nicoϋnic acid
To a suspension of methyl 6-(6-Methyl-pyridin-3-ylamino)-nicotinate (2.72 g, 11.18 mmol) in methanol (55 mL) is added 2M NaOH (17 mL). The reaction mixture is heated to 60 0C for 30 min. After 15 min a clear reddish solution is formed. Then, the reaction flask is placed in an ice bath and 2M HCI (17 mL) is added at such a rate that the internal temperature does not exceed 200C. After evaporation of methanol the suspension is diluted with water (50 mL). The product is filtered off, washed with cold water and vacuum dried at 600C over night to give a pink powder (2.78 g, 100%).
Following the same procedure, the following compounds can be prepared:
Example 4.2: Azepan-1-yl-f6-(4-chloro-phenvlamino)-pvridin-3-vlJ-methanone Yellow foam, TLC: Rf = 0.25 (MTBE), HPLC: tR = 6.5 min (system 1); ESI+ MS: m/z = 330.5 (MH+).
Example 4.3: [6-(4-Chloro-phenylamino)-pyridin-3-yl]-(3, 3-difluoro-piperidin- 1 -yl)-
methanone
Colorless crystals, TLC: Rf = 0.23 (MTBE), HPLC: tR = 6.1 min (system 1); ESI+ MS: m/z = 352.6 (MH+).
Example 4.4: f6-(4-Chloro-phenvlamino)-Dvridin-3-vll-(4-methyl-piperidin-1-vl)-methanone
Colorless crystals, TLC: Rf = 0.3 (MTBE), HPLC: tR = 6.6 min (system 1); ESI+ MS: m/z = 330.6 (MH+).
Example 4.5: [6-(4-Chloro-phenvlamino)-pvridin-3-vl]-(3.5-dimethyl-piperidin-1-yl)- methanone (diastereomeric mixture cis / trans 72:28)
Colorless crystals, TLC: Rf = 0.35 (MTBE), HPLC: tR = 6.9 min (trans diastereomer, 28%), 7.0 min (cis diastereomer, 72%) (system 1 ); ESI+ MS: m/z = 344.6 (MH+).
Example 4.6: rac-l6-(4-Chloro-phenvlamino)-pvridin-3-vll-(3-hvdroxymethvl-piperidin-1-yl)- methanone
Colorless foam, TLC: Rf = 0.32 (MTBE-MeOH 9:1), HPLC: tR = 5.2 min (system 1 ); ESI+ MS: m/z = 346.5 (MH+).
Example 4.7: rac-(6-(4-Chloro-phenvlamino)-pvridin-3-vl]-(3-methoxv-piperidin-1~yl)- methanone
Colorless foam, TLC: R, = 0.43 (MTBE-MeOH 9:1 ), HPLC: tR = 5.8 min (system 1 ); ESI+ MS: m/z = 346.5 (MH+). Example 4.8: [β-ft-Chloro-phenylaminoj-pyridinS-ylJ-foctahydro-quinolin- 1 -yl)-meth
anone (diastereomeric mixture, cis / trans)
Colorless foam, TLC: Rf = 0.22, 0.29 (MTBE-MeOH 9:1), HPLC: tR = 7.3 min (system 1); ESI+ MS: m/z = 370.7 (MH+).
Example 4.9: (3-Aza-bicyclo[3.2.2]non-3-yl)-[6-(4-chloro-phenylamino)-pyridin-3-yl]- methanone
Foam, TLC: Rf = 0.28 (MTBE), HPLC: tR = 6.9 min (system 1); ESI+ MS: m/z = 356.6 (MH+).
Example 4.10: (2-Aza-tricyclo[3.3.1.1 *3, 7*]dec-2-yl)-[6-(4-chloro-phenylamino)-pyridin-3-yl]- methanone
Colorless crystals, TLC: Rf = 0.23 (MTBE), HPLC: tR = 7.0 min (system 1 ); ESI+ MS: m/z = 368.6 (MH+).
Example 4.11 : [6-(4-Chloro-phenylamino)-pyήdin-3-yl]-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8- yl)-methanone
Colorless foam, TLC: Rf = 0.36 (MTBE-MeOH 9:1 ), HPLC: tR = 5.4 min (system 1 ); ESI+ MS: m/z = 358.6 (MH+).
Example 4.12: rac-(2-Aza-bicyclo[2.2.1]hept-2-yl)-[6-(4-chloro-phenylamino)-pyhdin-3-yl]- methanone
Colorless crystals, TLC: Rf = 0.31 (MTBE-MeOH 95:5), HPLC: tR = 6.2 min (system 1 ); ESI+ MS: m/z = 328.6 (MH+). Example 4.13: rac-(3-Methyl-piperidin-1-yl)-(6-(6-methyl-pyridin-3-ylamino)-pyήdin-3-vlh methanone
Yellow foam, TLC: Rf = 0.26 (MTBE-MeOH 9:1), HPLC: tR = 4.4 min (system 1); ESI+ MS: m/z = 311.6 (MH+).
Using either S-3-methylpiperidine or f?-3-methylpiperidine as starting material the pure enantiomers could be prepared:
Example 4.13a: (S-3-Methvl-DiDehdin-1-yl)'f6-(6-methyl-pyridin-3-ylamino)-pyήdin-3-vll- methanone
Colorless foam, TLC: R, = 0.32 (MTBE-MeOH 85:15), HPLC: tR = 4.1 min (system 1); ESI+ MS: m/z = 311.2 (MH+).
Example 4.13b: (R-3-Methvl-piperidin-1-vl)-f6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yll- methanone
Colorless foam, HPLC: tR = 4.1 min (system 1 ); ESI+ MS: m/z = 311.2 (MH+).
Example 4.14: [6-(4-Chloro-phenylamino)-pyridin-3-yl]-(rel-(3aR, 4S, 7aR)-4-hydroxy-4-m- tolylethynyl-octahydro-indol-1-yl)-methanone
Yellow foam, TLC: Rf = 0.32 (MTBE-MeOH 95:5), HPLC: tR = 6.8 min (system 1 ); ESI+ MS: m/z = 486.7 (MH+).
Example 4.15: Azepan-1-vl-f6-(6-methyl-pyπdin-3-ylamino)-pyridin-3-yll-methanone
Yellow crystals, TLC: Rf = 0.2 (MTBE-MeOH 9:1), HPLC: tR = 4.0 min (system 1 ); ESI+ MS: m/z = 311.6 (MH+).
Example 4.16: Azocan-1-vl-f6-(6-methvl-pvridin-3-vlamino)-pyridin-3-vll-methanone
TLC: Rf = 0.33 (MTBE-MeOH 85:15), HPLC: tR = 4.5 min (system 1 ); ESI+ MS: m/z = 325.6 (MH+). Example 4.17: r5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vn-(2-ethvl-pipericlin-1 -vh- methanone
TLC: Rf = 0.13 (DCM/MeOH 95:5), HPLC: tR = 2.8 min (system 4); LC/MS MS: m/z = 359 (MH+).
Example 4.18: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((R)-2-ethyl-piperidin-1 - yl)-methanone
TLC: Rf = 0.81 (DCM/MeOH 5:1 ), HPLC: tR = 2.8 min (system 4); LC/MS MS: m/z = 359 (MH+); [a]D = -33.6° (c=1.0, CHCI3, 20 0C).
Example 4.19: [5-Chloro-6-(6-methvl-Dvridin-3-vlamino)-pvridin-3-vll-((S)-2-ethyl-piperidin-1- yl)-methanone
TLC: Rf = 0.81 (DCM/MeOH 95:5), HPLC: tR = 2.8 min (system 4); LC/MS MS: m/z = 359 (MH+), [σ]Hg578 = +1-64° (c=0.16, DCM1 20 0C).
Example 4.20: [δ-Chloro-β-fβ-methvl-pvridin-S-vlaminoi-pvridin-S-yli-te.S-dimethvl-piperidin- 1 -yl)-methanone
TLC: Rf = 0.75 (DCM/MeOH 5:1 ), HPLC: tR = 2.8 min (system 4); LC/MS MS: m/z = 359 (MH+).
Example 4.21 : [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((2S, 3S)-2, 3-dimethyl- piperidin- 1 -yl) -methanone
TLC: R, = 0.66 (DCM/MeOH 5:1 ), HPLC: tR = 2.76 min (system 4); LC/MS MS: m/z = 359 (MH+), [σ]Hg578 = +0.9° (c=0.11 , DCM, 20 0C). Example 4.22: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((2R, 3R)-2, 3-dimethyl- piperidin- 1 -yl)-methanone
TLC: Rf = 0.72 (DCM/MeOH 5:1 ), HPLC: tR = 2.76 min (system 4); LC/MS MS: m/z = 359 (MH+), [σ]Hg578 = -1 -0° (c=0.11 , DCM, 20 0C).
Example 4.23: [5-Chloro-&(6-methylφvήdin-3-vlamino)-pvridin-3-yll-((S)-2-methyl-piperidin- 1-yl)-methanone
TLC: Rf = 0.87 (DCM/MeOH 5:1), HPLC: tR = 2.65 min (system 4); LC/MS MS: m/z = 345 (MH+), [σ]Hg578 = +0.10° (c=0.67, DCM, 20 0C).
Example 4.24: [S-Chloro-G-fβ-methyl-pyridinS-ylaminol-pyridin-S-yll-ffRi^-methyl-piperidin- 1-yl)-methanone
TLC: Rf = 0.80 (DCM/MeOH 5:1), HPLC: tR = 2.65 min (system 4); LC/MS MS: m/z = 345 (MH+), [σ]Hg578 = -0.10° (c=0.67, DCM, 20 0C).
Example 4.25: fS-Chloro-β-fβ-methyl-pyridin-S-ylaminoj-pyridin-S-vll-foctahydro-filpyrindin- 1-yl)-methanone
TLC: Rf = 0.79 (DCM/MeOH 5:1), HPLC: tR = 2.76 min (system 4); LC/MS MS: m/z = 371 (MH+).
Example 4.26: f5-Chloro-6-(6-methyl-pvήdin-3-vlamino)-pyridin-3-vl]-(4aS, 7aS)-octahydro- [1]pyrindin-1 -yl-methanone
TLC: Rf = 0.64 (DCM/MeOH 5:1 ), HPLC: tR = 2.86 min (system 4); LC/MS MS: m/z = 371 (MH+), [σ]Hg578 = +0.12° (c=0.007, DCM, 20 °C).
Example 4.27: f5-Chloro-6-(6-methvl-pyridin-3-ylamino)-pyridin-3-vlh(4aR, 7aR)-octahydro- [1]pyrindin- 1 -yl-methanone TLC: Rf = 0.64 (DCM/MeOH 5:1), HPLC: tR = 2.84 min (system 4); LC/MS MS: m/z = 371 (MH+), [σ]Hg578 = -0.15° (c=0.007, DCM, 20 0C).
Example 4.28: [S-Chloro-β-fβ-methyl-pyridin-S-ylaminoypyridin-S-ylJ-fi-isopropyl-piperidin- 1 - yl)-methanone
TLC: Rf = 0.76 (DCM/MeOH 5:1 ), HPLC: tR = 2.90 min (system 4); LC/MS MS: m/z = 373 (MH+).
Example 4.29: !5-Chloro-6-(6-methvl-Dvridin-3-vlamino)-Dvridin-3-yll-((R)-2-isoDroDvl- piperidin-1-yl)-methanone
TLC: Rf = 0.63 (DCM/MeOH 5:1), HPLC: tR = 2.88 min (system 4); LC/MS MS: m/z = 373 (MH+), [σ]Hg578 = +0.72° (c=0.09, DCM, 20 0C).
Example 4.30: f5-Chloro-6-(6-methvl-Dvridin-3-vlamino)-pvridin-3-yll-((S)-2-isoDroDvl- piperidin~1-yl)-methanone
TLC: Rf = 0.63 (DCM/MeOH 5:1), HPLC: tR = 2.89 min (system 4); LC/MS MS: m/z = 373 (MH+), [σ]Hg578 = -0.79° (c=0.09, DCM, 20 0C).
Example 4.31 : f5-Chloro-6-(6-methvl-Dvridin-3-vlamino)-pvridin-3-vll-((R)-3-ethyl-DiDeridin-1- yl)-methanone
TLC: Rf = 0.30 (EtOAc/hexanes 1 :1), HPLC: tR = 2.83 min (system 4); LC/MS MS: m/z = 359 (MH+).
Example 4.32: f5-Chloro-6-(6-methvl-Dvridin-3-vlamino)-Dvhdin-3-vll-((S)-3-ethvl-DiDeridin-1- yl)-methanone
TLC: R, = 0.28 (EtOAc/hexanes 1:1 ), HPLC: tR = 2.86 min (system 4); LC/MS MS: m/z = 359 (MH+). Example 4.33: fδ-Chloro-β-fβ-methvl-pvridin-d'Vlaminokpvridin-d-vlJ-O-cvclopropyl-pipeήdin- 1-yl)-methanone
TLC: R, = 0.51 (DCM/MeOH 5:1), HPLC: tR = 2.90 min (system 4); LC/MS MS: m/z = 373 (MH+).
The starting material can be prepared as described hereafter:
i) 3-Cyclopropyl-piperidine hydrochloride
3-Cyclopropyl pyridine (820 mg, 5.27 mmol) was hydrogenated in a mixture of MeOH (15mL) and concentrated aqueous hydrochloric acid (0.58 mL) in the presence of Nishimura catalyst (70 mg) under atmospheric pressure for 22 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM. The organic phases were combined, dried over sodium sulfate, acidified by addition of ethanolic hydrochloric acid, and concentrated in vacuo to afford 3-cyclopropyl piperidine hydrochloride (694 mg, 82%) as colorless crystals. TLC: R, = 0.49 (DCM/MeOH 5:1 ), LC/MS MS: m/z = 126 (MH+).
Example 4.34: f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll-(2-propyl-piperidin-1-vl)- methanone
TLC: Rf = 0.84 (DCM/MeOH 5:1 ), HPLC: tR = 2.95 min (system 4); LC/MS MS: m/z = 373 (MH+).
Example 4.35: f5-Chloro-6-(6-methvl-pvhdin-3-vlamino)-pvridin-3-vl]-((S)-2-propyl-piperidin- 1-yl)-methanone
TLC: Rf = 0.69 (DCM/MeOH 5:1), HPLC: tR = 2.97 min (system 4); LC/MS MS: m/z = 373 (MH+), MH9578 = +1.17° (c=0.09, DCM, 20 0C).
Example 4.36: f5-Chloro-6-(6-methvl-pvridtn-3-vlarnino)-pvridin-3-vlh((R)-2-propyl-piperidin- 1-yl)-methanone TLC: R, = 0.61 (DCM/MeOH 5:1 ), HPLC: tR = 2.97 min (system 4); LC/MS MS: m/z = 373 (MH+), [a]Hg578 = -1 -17° (c=0.09. DCM, 20 0C).
Example 4.37: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3~yl]-(2, 3-diethyl-piperidin-1 - yl)-methanone
TLC: Rf = 0.21 (EtOAc/hexanes 1 :1), HPLC: tR = 3.08 min (system 4); LC/MS MS: m/z = 387 (MH+).
Example 4.38: (2-Butyl-piperidin-1-yl)-[5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]- methanone
TLC: Rf = 0.22 (DCM/MeOH 5:1), HPLC: tR = 3.09 min (system 4); LC/MS MS: m/z = 387 (MH+).
Example 4.39: f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll-f2-(1-ethvl-propyl)- piperidin- 1 -yl]-methanone
TLC: Rf = 0.87 (DCM/MeOH 95:5), HPLC: tR = 3.19 min (system 4); LC/MS MS: m/z = 401 (MH+).
Example 4.40: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll-(2-ethvl-3-methyl- piperidin-1-yl)-methanone
TLC: Rf = 0.22 (EtOAc/hexanes 3:1), HPLC: tR = 2.89 min (system 4); LC/MS MS: m/z = 373 (MH+).
The starting material was prepared as described hereafter:
i) 2-Etyhl-3-methyl-pyridine
2-Ethyl-3-methylpyridine was prepared by Suzuki coupling of 2-bromo-3-methylpyridine and ethylboronic acid according to the procedure given in Tetrahedron Letters 2002, 43, 6987- 6990. The desired product was obtained in 52% yield after purification on silica gel. ii) 2-Etyhl-3-methyl-piperidine hydrochloride
2-Ethyl-3-methyl pyridine (1.75 g, 11.1 mmol) was hydrogenated in a mixture of MeOH (32 mL) and concentrated aqueous hydrochloric acid (1.2 ml_) in the presence of Nishimura catalyst (180 mg) under atmospheric pressure for 22 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM. The organic phases were combined, dried over sodium sulfate, acidified by addition of ethanolic hydrochloric acid, and concentrated in vacuo to afford 2-ethyl-3-methyl piperidine hydrochloride (1.60 g, 88%) as colorless crystals.
Example 4.41 : \5-Ch\oro-6AQ-meihv\-pyridm' -3-y\ammo)-pyr\din-3-wl]A2-phenyl-piper\dir\-1- yl)-methanone
TLC: Rf = 0.34 (EtOAc/hexanes 3:1), HPLC: tR = 1.85 min (system 5); LC/MS MS: m/z = 407 (MH+).
Example 4.42: [5-Ch\oro-Q-(6-methy\-pyridm' -3-y\amm' o)-pyridm' -3-y\]-{3A, 5, 6-tetrahydro-2H- [2,2']bipyridinyl-1-yl)-methanone
TLC: Rf = 0.17 (EtOAc/hexanes 3:1), HPLC: tR = 2.29 min (system 5); LC/MS MS: m/z = 408 (MH+).
Example 4.43: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(3, 4, 5, 6-tetrahydro-2H- [2,3']bipyridinyl-1-yl)-methanone
TLC: Rf = 0.25 (DCM/MeOH 9:1 ), HPLC: tR = 2.11 min (system 5); LC/MS MS: m/z = 408 (MH+).
Example 4.44: f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pyridin-3-vll-f2-(tetrahvdro-furan-2- yl)-piperidin-1-yl]-methanone TLC: Rf = 0.34 (DCM/MeOH 9:1), HPLC: tR = 2.62 min (system 4); LC/MS MS: m/z = 401 (MH+).
Example 4.45: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vlh[2-(5-methyl-furan-2-vl)- piperidin-1-yl]-methanone
TLC: Rf = 0.63 (DCM/MeOH 9:1), HPLC: tR = 3.00 min (system 4); LC/MS MS: m/z = 411 (MH+).
Example 4.46: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-yll-(2-oxazol-2-yl-piperidin- 1-yl)-methanone
TLC: Rf = 0.55 (DCM/MeOH 9:1), HPLC: tR = 2.66 min (system 4); LC/MS MS: m/z = 414 (MH+).
Example 4.47: f2-(2-Chloro-ethvl)-pipehdin-1-vn-[5-chloro-6-(6-methvl-pyridin-3-vlamino)- pyridin-3-yl]-methanone
TLC: Rf = 0.33 (DCM/MeOH 5:1 ), HPLC: tR = 0.76 min (system 4); LC/MS MS: m/z = 394 (MH+).
Example 4.48: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll-(2,6-dimethyl-piperidin- 1-yl)-methanone
TLC: Rf = 0.25 (EtOAc/hexanes 3:1 ), HPLC: tR = 3.03 min (system 3); LC/MS MS: m/z = 359 (MH+).
Example 4.49: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2, 2, 6, 6-tetramethyl- piperidin~1-yl)-methanone
TLC: Rf = 0.44 (EtOAc/hexanes 3:1 ), HPLC: tR = 3.14 min (system 4); LC/MS MS: m/z = 387 (MH+). Example 4.50: f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pyridin-3-vll-(2-methvl-6-roDvl- piperidin-1-yl)-methanone
TLC: Rf = 0.35 (EtOAc/hexanes 3:1 ), HPLC: tR = 2.13 min (system 5); LC/MS MS: m/z = 387 (MH+).
Example 4.51 : [5-Chtoro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll-((2R.6R)-2-ethyl-6- propyl-piperidin- 1 -yl)-methanone
TLC: R, = 0.45 (EtOAc/hexanes 3:1 ), HPLC: tR = 2.25 min (system 5); LC/MS MS: m/z = 387 (MH+).
Example 4.52: ϊ5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vl]-(5-methvl-2-ropyl- piperidin-1 -yl)-methanone
TLC: Rf = 0.40 (EtOAc/hexanes 3:1 ), HPLC: tR = 2.06 min (system 5); LC/MS MS: m/z = 387 (MH+).
The starting material was prepared as described hereafter:
i) 5-Methyl-2-propyl-pyridine
5-Methyl-2-propyl-pyridine was prepared by Suzuki coupling of 2-bromo-5-methylpyridine and propylboronic acid according to the procedure given in Tetrahedron Letters 2002, 43, 6987-6990. The desired product was obtained in 24% yield after purification on silica gel.
ii) 5-Methyl-2-propyl-piperidine hydrochloride
5-Methyl-2-propyl-pyridine (345 mg, 2.55 mmol) was hydrogenated in a mixture of MeOH (10 mL) and concentrated aqueous hydrochloric acid (0.29 mL) in the presence of Nishimura catalyst (50 mg) under atmospheric pressure for 40 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM. The organic phases were combined, dried over sodium sulfate, acidified by addition of ethanolic hydrochloric acid, and concentrated in vacuo to afford 2-methyl-3-propyl piperidine hydrochloride (0.43 g, 95%) as beige crystals.
Example 4.53: f5-Chloro-6-(4-chloro-phenvlamino)-Dvridin-3-vl]-(octahvdro-1lpvrindin-1-vl)- methanone
TLC: Rf = 0.71 (DCM/MeOH 95:5), HPLC: tR = 3.85 min (system 5); LC/MS MS: m/z = 391 (MH+).
Example 4.54: [5-Chloro-6-(4-chloro-phenvlamino)-pvήdin-3-vlh((R)-2-ethyl-piperidin-1-vl)- methanone
TLC: Rf = 0.75 (DCM/MeOH 95:5), HPLC: tR = 3.78 min (system 5); LC/MS MS: m/z = 379 (MH+).
Example 4.55: f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll-(2-vinyl-piperidin-1-vl)- methanone
TLC: Rf = 0.78 (DCM/MeOH 95:5), HPLC: tR = 2.70 min (system 4); LC/MS MS: m/z = 357 (MH+).
Example 4.56: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll-[((Z)-2-propenyl)- piperidin-1-yl]-methanone
TLC: Rf = 0.66 (DCM/MeOH 95:5), HPLC: tR = 2.88 min (system 4); LC/MS MS: m/z = 371 (MH+).
Example 4.57: [S-Chloro-β-fβ-methvl-pyridin-S-vlaminoj-pvridinS-vll-β-ethvlidene-piperidin- 1-yl]-methanone
TLC: Rf = 0.89 (DCM/MeOH 5:1), HPLC: tR = 2.85 min (system 4); LC/MS MS: m/z = 357 (MH+). The starting material was prepared as described hereafter:
i) 3-Ethylidene-piperidine hydrochloride
To a solution of potassium-tert-butoxide (3.10 g, 27.6 mmol, 1.1 eq) in THF (30 ml_) at rt was added sequentially ethyltriphenylphosphoniumbromide (11.0 g, 29.6 mmol, 1.18 eq) followed by a solution of 1-(tert-Butoxycarbonyl)-3-piperidone (5.0 g, 25.1 mmol) in THF (20 ml_). After stirring the resulting suspension for 24 h at rt, water was added and the aqueous phase was extracted with DCM. The organic phases were combined, dried over sodium sulfate and the solvent removed on vacuo. After purification by flash chromatography, 3-ethylidene- piperidine-1-carboxylic acid tert-butyl ester (5.5 g, 100%) was obtained as a 1:2 E/Z isomeric mixture. Deprotection of the Boc-group was effected by stirring 3-ethylidene-piperidine-1- carboxylic acid tert-butyl ester (5.5 g, 26 mmol) in HCI/dioxane (4M, 15 mL) for 1 h at rt. The white precipitate was filtered off, washed twice with diethyl ether and dried on vacuo to afford the desired product as beige crystals (2.99 g, 78%). LC/MS MS: m/z = 111 (MH+).
Example 4.58: fδ-Chloro-β-fβ-methyl-pyridin-S-vlaminoypyridin-S-yll-fS-propylidene-piperidin- 1-yl]-methanone
TLC: Rf = 0.16 (DCM/MeOH 95:5), HPLC: tR = 2.85 min (system 4); LC/MS MS: m/z = 371 (MH+).
3-Propylidene-piperidine hydrochloride was prepared in an overall yield of 71% starting from propyltriphenylphosphoniumbromide and 1-(tert-Butoxycarbonyl)-3-piperidone in analogy to the procedure given in Example 4.57 i. LC/MS MS: m/z = 126 (MH+).
Example 4.59: [5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vl1-(2-ethoxvmethyl- piperidin- 1 -yl) -methanone
TLC: Rf = 0.66 (DCM/MeOH 95:5), HPLC: tR = 2.88 min (system 4); LC/MS MS: m/z = 371 (MH+).
ExamB\e_4Jfo [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-thoxymethyL piperidin- 1 -yl) -methanone TLC: Rf = 0.26 (DCM/MeOH 95:5), HPLC: tR = 2.55 min (system 4); LC/MS MS: m/z = 389 (MH+).
Example 4.61 : f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll-f2-(2-hydroxv-ethyl)- piperidin- 1 -yl]-methanone
TLC: Rf = 0.23 (DCM/MeOH 95:5), HPLC: tR = 2.72 min (system 4); LC/MS MS: m/z = 375 (MH+).
Example 4.62: f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pvhdin-3-vl]-(5-fluoro-2-propyl- piperidin-1-yl)-methanone
TLC: Rf = 0.35 (EtOAc/hexanes 2:1 ), HPLC: tR = 1.60 min (system 5); LC/MS MS: m/z = 391 (MH+).
The starting material was prepared as described hereafter:
i) 5-Fluoro-2-propyl pyridine
To a suspension of n-propylmagnesium chloride (13 mL, 1.0 M in diethyl ether) and zinc chloride (17 mL, 0.5 M in THF, 2.5 eq) was added 1-methyl-2-pyrrolidinone (10 mL), 2- bromo-5-fluorpyridine (600 mg, 3.41 mmol) and bis(tri-tert.-butylphosphine)palladium (174 mg, 0.34 mmol, 0.1 eq). After stirring at 80 0C for 3 h the mixture was cooled to 00C, water was added resulting solution extracted with EtOAc twice. The organic phases were combined, dried over sodium sulfate and the solvent removed on vacuo. After purification by flash chromatography, 5-fluoro-2-propyl pyridine (182 mg, 30%) was obtained. LC/MS MS: m/z = 140 (MH+).
ii) 5-Fluoro-2-propyl-piperidine hydrochloride
5-Fluoro-2-propyl pyridine (182 mg, 1.04 mmol) was hydrogenated in a mixture of MeOH (10 mL) and concentrated aqueous hydrochloric acid (0.13 mL) in the presence of Nishimura catalyst (50 mg) at 4 bar for 3.5 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM. The organic phases were combined, dried over sodium sulfate, acidified by addition of ethanolic hydrochloric acid, and concentrated in vacuo to afford a mixture of 5-fluoro-2-propyl-piperidine hydrochloride and 2-propyl- piperidine hydrochloride as light red solid (95%) which was used in the next step without further purification.
Example 4.63: f5-Chloro-6-(6-methvl-pvridin-3-vlamino)-pyridin-3-yll-f2-(1,2-difluoro-propyl)- piperidin-1-yl]-methanone and Example 4.64: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)- pyhdin-3-yl]-[2-(2-fluoro-propyl) -piperidin- 1 -yl]-methanone
Both compounds were isolated after preparative TLC separation of the corresponding mixture.
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-[2-(1,2-difluoro-propyl)-piperidin-1-yl]- methanone: TLC: Rf = 0.39 (EtOAc/hexanes 5:1), HPLC: tR = 1.37 min (system 5); LC/MS MS: m/z = 391 (MH+).
[S-Chloro-β-fβ-methyl-pyridin-S-ylaminoypyridin-S-ylJ-β-fi-fluoro-propyO-piperidin-i-yl]- methanone: TLC: Rf = 0.40 (EtOAc/hexanes 5:1), HPLC: tR = 1.22 min (system 5); LC/MS MS: m/z = 409 (MH+).
The starting material was prepared as described hereafter:
i) 2-(1 ,2-Difluoro-propenyl)-pyridine
To a solution of 1-pyridin-2-yl-propan-2-one (3.75 g, 27.7 mmol) in DCM (20 mL) at 00C was was DAST (10.1 mL, 69 mmol, 2.50 eq). After stirring the solution for 15 h (O°C->rt) it was diluted by DCM and subsequently quenched by slow addition of ice water. Resulting solution was extracted twice with DCM. The organic phases were combined, dried over sodium sulfate and the solvent removed on vacuo. After purification by flash chromatography 2-(1 ,2- difluoro-propenyl)-pyridine (616 mg, 14%) was obtained as beige oil. LC/MS MS: m/z = 156 (MH+).
ii) 2-(1,2-Difluoro-propyl)-piperidine hydrochloride, 2-(1-fluoro-propyl)-piperidine hydro- chloride and 2-propyl-piperidine hydrochloride 2-(1 ,2-Difluoro-propenyl)-pyridine (820 mg, 4.28 mmol) was hydrogenated in a mixture of MeOH (25 ml_) and concentrated aqueous hydrochloric acid (0.46 mL) in the presence of Nishimura catalyst (100 mg) at atmospheric pressure for 24 hours. The mixture was filtered through a pad of celite and washed with MeOH. The solvent was removed in vacuo and the residue was dissolved in water. The aqueous solution was first washed with DCM, than basified by addition of 40% NaOH solution and extracted twice with DCM. The organic phases were combined, dried over sodium sulfate, acidified by addition of ethanolic hydrochloric acid, and concentrated in vacuo to afford a mixture of 2-(1 ,2-difluoro-propyl)- piperidine hydrochloride, 2-(1-fluoro-propyl)-piperidine hydrochloride and 2-propyl-piperidine hydrochloride as light red solid (100%) which was used in the next step without further purification.
Example 4.65: r5-Chloro-6-(6-methvl-pvridin-3-ylamino)-pvridin-3-vl]-(2-ethyl-f1,3lo
xazepan-3-yl)-methanone
TLC: Rf = 0.21 (DCM/MeOH 95:5), HPLC: tR = 2.66 min (system 4); LC/MS MS: m/z = 375 (MH+).
Example 4.66: f5-Chloro-6-(6-methvl-pyridin-3-vlamino)-pyridin-3-ylh(2-propyl- [1, 3]oxazepan-3-yl)-methanone
TLC: Rf = 0.2 (DCM/MeOH 95:5), HPLC: tR = 2.82 min (system 4); LC/MS MS: m/z = 389 (MH+).
Example 4.67: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pvridin-3-vl]-f2-(1-ethyl-propyl)- [1 ,3]oxazepan-3-yl]-methanone
TLC: R, = 0.17 (DCM/MeOH 95:5), HPLC: tR = 3.10 min (system 4); LC/MS MS: m/z = 417 (MH+).
Example 4.68: [5-Ch\oro-Q-{Q-methy\-pyr\din-3-y\amm' o)-pyήdm' -3-y\]-{2-propy\-[1,3]oxazinan- 3-yl)-methanone
TLC: Rf = 0.11 (DCM/MeOH 95:5), HPLC: tR = 2.55 min (system 4); LC/MS MS: m/z = 375 (MH+).
Example 4.69: f5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-vll-f2-(1-ethyl-propyl)- [1 ,3]oxazinan-3-yl]-methanone TLC: Rf = 0.18 (DCM/MeOH 95:5), HPLC: tR = 2.89 min (system 4); LC/MS MS: m/z = 403 (MH+).
Exa m pie 4.70 : (2-Butyl-[1 , 31oxazinan-3-yl) -[5-chloro-6-(6-meth yl-p yridin-3-ylamino)-p yήdin-3- yl]-methanone
TLC: Rf = 0.12 (DCM/MeOH 95:5), HPLC: tR = 2.87 min (system 4); LC/MS MS: m/z = 389 (MH+).
Example 4.71 : f5-Chloro-6-(6-methyl-pyridin-3-ylamino)~pyridin-3-ylhf2-(2-methoxy-ethyl)- piperidin- 1 -yl]-methanone
TLC: Rf = 0.15 (DCM/MeOH 95:5), HPLC: tR = 2.60 min (system 4); LC/MS MS: m/z = 389 (MH+).
Example 4.72: f5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyήdin-3-ylh(2-phenyl-pyrrolidin-1- yl)-methanone
TLC: R, = 0.66 (DCM/MeOH 9:1), HPLC: tR = 3.07 min (system 3); LC/MS MS: m/z = 393 (MH+).
Example 4.73: [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-pyridin-2-yl- pyrrolidin-1-yl)-methanone
TLC: Rf = 0.65 (DCM/MeOH 9:1), HPLC: tR = 2.48 min (system 3); LC/MS MS: m/z = 394 (MH+).
Example 4.74: f5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((R)-2-ethoxy-pyrrolidin- 1-yl)-methanone
TLC: Rf = 0.44 (DCM/MeOH 9:1 ), HPLC: tR = 2.09 min (system 3); LC/MS MS: m/z = 361 (MH+).
Example 4.75: f5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyhdin-3-yll-f2-(5-methyl-thiophen-2- yl)-pyrrolidin- 1 -yl]-methanone
TLC: R, = 0.5 (DCM/MeOH 9:1 ), HPLC: k = 3.15 min (system 3); LC/MS MS: m/z = 413 (MH+).
Example 4.76: f5-Chloro-6-(6-methyl-pyndin-3-ylamino)-pyridin-3-yl]-(2-propyl-azepan-1-yl)- methanone TLC: R, = 0.52 (DCM/MeOH 95:5), HPLC: tR = 3.21 min (system 3); LC/MS MS: m/z = 387 (MH+).
Example 4.77: rS-Chloro-β-fβ-methvl-pvridin-S-vlaminoϊ-pvridin-S-vlHS-propvl-morpholin-^ yl)-methanone
TLC: R, = 0.18 (DCM/MeOH 95:5), HPLC: tR = 2.53 min (system 4); LC/MS MS: m/z = 375 (MH+).
Example 5.1 : Azepan-1-vl-[5-chloro-6-(4-chloro-Dhenvlamino)-pvridin-3-vll-methanone
To a solution of 5-Chloro-6-(4-chloro-phenylamino)-nicotinic acid (72 mg, 0.25 mmol) and DIPEA (67 μL, 0.38 mmol) in 1 ,2-dimethoxyethane (1.2 mL) is added HATU (97 mg, 0.25 mmol) in one portion. The reaction mixture is stirred for 30 min at RT. Then, hexamethylene imine (24 μL, 0.2 mmol) is injected and stirring is continued for further 6h. The reaction mixture is evaporated to dryness and the residue is purified by preparative HPLC (YMC Pack
Pro C18 5 μm, 150 x 30 mm; AcN-H2O-0.1% TFA gradient 10% -> 100% AcN; flow: 20 mL min"1). The fractions containing the product are combined and acetonitrile is evaporated. The remaining aqueous solution is made alkaline by addition of solid NaHCO3 and extracted with ethyl acetate. The organic layer is separated, washed with brine, dried over Na2SO4, and evaporated to dryness to afford the title compound as a colorless powder (75 mg, 81%),
HPLC: tR = 7.0 min (system 1); ESI+ MS: m/z = 364.0, 366.0 (MH+).
The starting material can be prepared as described hereafter.
5-Chloro-6-(4-chloro-phenylamino)-nicotinic acid
A solution of δ.θ-dichloronicotinic acid (0.5 g, 2.55 mmol) and 4-chloroaniline (293 mg, 2.30 mmol) in glacial acetic acid (5 mL) is microwave heated to 150 0C for 75 min. To the clear solution is added ethyl acetate (10 mL). After a short time the product starts to crystallize. The precipitate is filtered off, washed with ethyl acetate, and vacuum dried at room temperature to afford the desired product as a colorless powder (470 mg, 65%).
Following the same procedure, the following compounds can be prepared: Example 5.2: rac-f5-Chloro-6-(4-chloro-phenvlamino)-pvridin-3-yll-(3-methvl-piperidin-1-yl)- methanone
Colorless syrup, HPLC: tR = 7.2 min (system 1 ); ESI+ MS: m/z = 364.0, 366.0 (MH+).
Using either S-3-methylpiperidine or R-3-methylpiperidine as starting material the pure enantiomers could be prepared:
Example 5.2a: f5-Chloro-6-(4-chloro-phenvlamino)-pyridin-3-yll-(S-3-methyl-piperidin-1-yl)- methanone
Brown gum, HPLC: tR = 7.4 min (system 1 ); ESI+ MS: m/z = 364.0, 366.0 (MH+).
Example 5.2b: [δ-Chloro-β^-chloro-phenylamino^pyridin-S-ylHR-S-methyl-piperidin-i-yl)- methanone Brown gum, HPLC: tR = 7.3 min (system 1); ESI+ MS: m/z = 364.0, 366.0 (MH+).
Example 5.3: Azepan-1~vl-[2-(4-chloro-phenvlamino)-pyrimidin-5-vl1-methanone Colorless crystals, HPLC: tR = 6.4 min (system 1 ); ESI+ MS: m/z = 331.5 (MH+).
Example 5.4: f2-(4-Chloro-phenvlamino)-pvrimidin-5-vll-piperidin-1-yl-methanone Colorless crystals, HPLC: tR = 6.2 min (system 1); ESI+ MS: m/z = 317.6 (MH+).
Example 5.5: rac-[2-(4-Chloro-phenylamino)-pyrimidin-5-yl]-(3-methyl-piperidin- 1-yl)- methanone
Colorless crystals, HPLC: tR = 6.5 min (system 1); ESI+ MS: m/z = 331.6 (MH+).
Example 6.1 : Azepan-1-vl-[6-(4-chloro-phenvlamino)-5-methoxv-pyridin-3-vll-methanone To a solution of azepan-1-yl-(6-chloro-5-methoxy-pyridin-3-yl)-methanone (198 mg, 0.70 mmol) and 4-chloroaniline (270 mg, 2.11 mmol) in toluene (5 mL) is added finely ground anhydrous K2CO3 (491 mg, 3.52 mmol). To the suspension obtained is added a still warm solution prepared by dissolving palladium(ll) acetate (10 mg, 0.04 mmol) and BINAP (27 mg,
0.04 mmol) in toluene (1 mL) with stirring for 20 min at 900C. The reaction mixture is stirred under argon for 21 h at 80 0C. After cooling ethyl acetate (40 mL) is added and the solution is extracted with water (3x 15 ml_). The organic layer is isolated, dried over Na2SO4 and evaporated to dryness to give a dark green oil. The crude product is purified by flash chromatography (24 g silica gel, MeOH-MTBE gradient 2% -> 15% MeOH, flow 20 mL min1). Recrytallization from Et2O gives the desired compound as beige crystals, TLC: Rf = 0.14 (MTBE), HPLC: tR = 7.0 min (system 1 ); ESI+ MS: m/z = 360.1 (MH+).
The starting material can be prepared as described hereafter:
i) β-chloroS-methoxynicotinic acid
To a solution of methyl 6-chloro-5-hydroxynicotinate (0.95 g, 5.07 mmol, prepared according to WO 00/51614) in DMSO (9.5 mL) is added powdered 85% KOH (0.67 g, 10.1 mmol) followed by slow injection of methyl iodide (0.35 mL, 5.57 mmol). The reaction mixture is stirred over night at RT. To achieve complete hydrolysis of the intermediate ester water (1 mL) is added and stirring is continued for further 30 min. The solution is diluted with 1M HCI
(100 mL) and extracted with ethyl acetate (1x 100 mL, 3x 50 mL). The combined organic extracts are dried over Na2SO4 and evaporated to give a yellow solid residue. Trituration with
H2O (20 mL) followed by drying in vacuo at 65°C affords the title compound as beige powder
(846 mg, 89%).
H) Azepan-1-yl-(6-chloro-5-methoxy-pyridin-3-yl)-methanone
A mixture of e-chloro-δ-methoxynicotinic acid (272 mg, 1.45 mmol) and thionyl chloride (3.2 mL) is stirred for 30 min at 75 0C. The clear solution is evaporated to dryness and the residue is redissolved in DCM (4 mL) under argon. After the addition of triethylamin (2 mL, 14.5 mmol) and hexamethyleneamine (0.2 mL, 1.74 mmol) the yellow turbid reaction mixture is stirred for 1h at RT. Then MTBE (30 mL) is added and the solution is extracted with H2O (3x 10 mL), dried over Na2SO4 and evaporated to give the title compound as a yellow oil (407 mg, 100%). The material can be used in the next step without further purification.
Following the same procedure, the following compounds can be obtained: Example β.2: Azepan-1-yl-f5-methoxv-6-(6-methvl-pvridin-3-vlamino)-pvridin-3-vll- methanone]
Yellow lyophilisate, TLC: Rf = 0.16 (MTBE-MeOH 9:1), HPLC: tR = 4.5 min (system 1 ); ESI+ MS: m/z = 341.1 (MH+).
Example 6.3: fβ-f^Chloro-phenylaminoiS-methoxv-pyridin-d-vll-piperidin-i-yl-methanone
Yellowish crystals, TLC: Rf = 0.13 (MTBE), HPLC: tR = 6.9 min (system 1); ESI+ MS: m/z = 346.1 (MH+).
Example 6.4: [5-Methoxy-6-(6-methyl-pyhdin-3-ylamino)-pyπdin-3-yl]-piperidin-1-yl- methanone
Yellowish lyophilisate, TLC: Rf = 0.15 (MTBE-MeOH 9:1), HPLC: t« = 4.0 min (system 1 ); ESI+ MS: m/z = 327.1 (MH+).
Example 6.5: Azepan-1-yl-[6-(4-chloro-phenylamino)-5-ethoxy-pyndin-3-yl]-methanone
Colorless lyophilisate, TLC: R, = 0.29 (MTBE), HPLC: tR = 7.4 min (system 1); ESI+ MS: m/z = 374.1 (MH+).
Example 6.6: Azepan-1-vl-f5-ethoxv-6-(6-methvl-pvήdin-3-vlamino)-pyhdin-3-vl]-methanone Colorless lyophilisate, TLC: R, = 0.25 (MTBE-MeOH 9:1), HPLC: tR = 4.6 min (system 1); ESI+ MS: m/z = 355.2 (MH+).
Example 6.7: f5-Ethoxy-6-(6-methvl-pvridin-3-vlamino)-pyridin-3-vll-piperidin-1-yl-methanone
Colorless lyophilisate, TLC: Rf = 0.21 (MTBE-MeOH 9:1), HPLC: tR = 4.4 min (system 1); ESI+ MS: m/z = 341.2 (MH+).
Example 7.1 : [δ-Chloro-β-ζβ-chloro-pyridin^-ylaminoypyridin^-ylJ-β-methyl-piperidin- 1 -yl)- methanone
A solution of 5-[3-Chloro-5-(3-methyl-piperidine-1-carbonyl)-pyridin-2-ylamino]-1H-pyridin-2- one (88 mg, 0.25 mmol) and DMAP (5 mg, 0.04 mmol) in phosphoryl chloride (2.75 mL) is refluxed under argon for 90 h. After cooling the suspension obtained is evaporated and taken up in DCM (40 mL) - 20% KHCO3 solution (40 mL). The organic layer is washed (1x 20% KHCO3, 40 mL; 2x H2O, 20 mL), dried over Na2SO4 and evaporated to give a reddish turbid syrup. The crude material is purified by flash chromatography (25 g silica gel, eluent MTBE, flow 20 mL min") to afford a bluish foam (37 mg, 40%), TLC: R, = 0.39 (MTBE), HPLC: tR = 6.4 min (system 1 ); ESI+ MS: m/z = 365.0 (MH+).
The starting material can be prepared as described hereafter:
5-[3-Chloro-5-(3-methyl-piperidine- 1 -carbonyl) -pyridin-2-ylamino]- 1 H-pyridin-2-one
To a solution of [5-Chloro-6-(6-methoxy-pyridin-3-ylamino)-pyridin-3-yl]-(3-methyl-piperidin-1- yl)-methanone (489 mg, 1.36 mmol, prepared from 5,6-dichloronicotinic acid, 3- methylpiperidine and 3-amino-6-methoxypyridine according to the procedure given in example 5.1 ) in 1 ,2-dichloroethane (30 mL) is added iodotrimethyl silane (0.47 mL, 3.39 mmol) in one portion. The reaction mixture is stirred for 6 h at 700C under argon. After cooling the reaction is quenched with methanol (3 mL) stirred for 15 min at RT and evaporated. The residue is taken up in a mixture of DCM (40 mL) and triethyl amine (1 mL), extracted (1x H2O, 20 mL; 1x 5% NaS2O3, 20 mL, 1x H2O, 20 mL), dried over Na2SO4 and evaporated to afford greenish residue. The crude product is purified by flash chromatography (54 g silica gel, MeOH-DCM gradient 0% -> 10% MeOH, flow 40 mL min"1) to afford a beige foam (401 mg, 85%).
Example 8.1 : f6-(4-Chloro-phenvlamino)-Dvridazin-3-vll-Dipehdin-1-vl-methanone
To a solution of 6-(4-Chloro-phenylamino)-pyridazine-3-carboxylic acid (50 mg, 0.2 mmol) and DIPEA (53 μL, 0.3 mmol) in DMA (1 mL) is added HATU (76 mg, 0.2 mmol) in one portion. The reaction mixture is stirred for 30 min at RT. Then piperidine (16 uL, 0.16 mmol) is injected and stirring is continued for further 6 h. The solution is diluted with ethyl acetate
(20 mL), extracted (2x brine, 20 mL), dried over Na2SO4 and evaporated to dryness to give an olive solid. The crude product is purified by flash chromatography (1O g silica gel, ETOAC-hexanes gradient 0% -> 80% ETOAC, flow 15 mL min'1) followed by crystallization from ether / hexanes to afford the title compound as beige powder (21 mg, 33%), HPLC: tR =
5.8 min (system 1); ESI+ MS: m/z = 317.5 (MH+).
The starting material can be prepared as described hereafter:
6-(4-Chloro-phenylamino)-pyridazine-3-carboxylic acid A solution of e-chloropyridazine-S-carboxylic acid (0.5 g, 3.15 mmol, [5096-73-1]) and 4- chloroaniline (805 mg, 6.31 mmol) in 1 ,2-dimethoxyethane (5 mL) is microwave heated for 20 min at 100 0C. After cooling the reaction mixture is diluted with ethyl acetate (10 mL) and stirred for 5 min. The brown precipitate is filtered off and triturated with cold water (30 mL). The light brown suspension is filtered and washed with water. After vacuum dry at 45°C the product is obtained as a beige powder (250 mg, 32%).
Following the same procedure, the following compounds can be obtained:
Example 8.2: rac-[6-(4-Chloro-phenylamino)-pyridazin-3-yl]-(3-methyl-piperidin-1-yl)- methanone
Gray powder, HPLC: tR = 6.1 min (system 1); ESI+ MS: m/z = 331.6 (MH+).
Example 8.3: [6-(4-Chloro-phenylamino)-pyridazin-3-yl]-(3, 3-dimethyl-piperidin-1-yl)- methanone
Beige powder, HPLC: tR = 6.3 min (system 1 ); ESI+ MS: m/z = 345.6 (MH+).
Example 8.4: f6-(4-Chloro-Dhenvlamino)-pvridazin-3-vl]-(3.4-dihvdro-1H-isoQuinolin-2-yl)- methanone Beige powder, HPLC: tR = 6.4 min (system 1); ESI+ MS: m/z = 365.6 (MH+).
Example 8.5: f6-(4-Chloro-Dhenvlamino)-pvridazin-3-vll-(4-methvl-Diperidin-1-vl)-methanone Gray powder, HPLC: tR = 6.1 min (system 1 ); ESI+ MS: m/z = 331.6 (MH+).
Example 9.1 : [5-Methyl-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-piperidin-1-yl-methanone
To a solution of 5-methyl-6-(6-methyl-pyridin-3-ylamino)-nicotinic acid (130 mg, 0.534 mmol) in DMF (15 mL), HOBt (106 mg, 0.74 mmol) and 4-methylmorpholine (180 μL, 1.61 mmol) were added. After 10 min of stirring, EDC (146 mg, 0.74 mmol) and piperidine (74.6 μL, 0.74 mmol) were added and the resulting mixture was stirred at 500C for 16 hours. The solvent was removed in vacuo and EtOAc was added. The organic phase was washed with a saturated solution of NaHCO3, dried over sodium sulfate and concentrated in vacuo to afford a brown resin. The crude product was purified by flash chromatography over silica gel using EtOAc as solvent to afford [5-methyl-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-piperidin-1- yl-methanone (30 mg, 18%) as a yellow resin.
The starting material was prepared as described hereafter:
i) N-tert-butyldimethylsilyl isopropyl formimidate
At -400C1 to a suspension of isopropyl formimidate hydrochloride (12.9 g, 105 mmol) in DCM
(150 ml_), triethylamine (32.3 mL, 231 mmol) was added in once. Then, a solution of tert- butyldimethylsilyl triflate (24.6 mL, 105 mmol) in DCM (100 mL) was added drop-wise with keeping the temperature below -400C. At the end of the addition, 25 mL of hexanes was added at once and the mixture was then allowed to reach RT. The precipitate was filtered off and washed with hexanes and DCM. The filtrate was concentrated in vacuo to afford a yellow paste. Et2O was added and the residual triethylammonium triflate was removed by decantation. The etheral phase was concentrated in vacuo to afford N-tert-butyldimethylsilyl isopropyl formimidate as a clear oil (15.53 g, 73.5%) which will be used without further purification.
ii) 6-Hydroxy-5-methyl-nicotinic acid ethyl ester At RT, a solution of propionyl chloride (1.55 mL, 17.4 mmol) in 3.5 mL of toluene was added drop-wise to a solution of N-tert-butyldimethylsilyl isopropyl formimidate (3.51 g, 17.4 mmol) and triethylamine (12.2 mL, 87 mmol) in 10 mL of toluene. The resulting mixture was stirred at RT for 2 hours and then 10 mL of hexanes was added. The precipitate was removed by filtration and washed with hexanes (3 x 5 mL). The solution was concentrated in vacuo to afford a clear oil. This oil was solubilised in toluene (15 mL) and ethyl propiolate (1.2 mL, 11.6 mmol) was added. The resulting mixture was stirred at 85°C for 70 hours. The mixture was concentrated in vacuo and then diluted with HCI 2N. The aqueous phase was extracted with DCM. The organic phases were combined, dried over sodium sulfate and concentrated in vacuo to afford a crude yellow paste (3.5 g). The crude product was purified by flash chromatography over silica gel using Hexanes/EtOAc (75/25 to 0/100) as solvent gradient to afford 6-hydroxy-5-methyl-nicotinic acid ethyl ester (1.65 g, 78.5%) as a yellow powder. (ES- MS: m/z 182.1 [M+H]+, tR 3.28 min (system 2)).
iii) 6-Chloro-5-methyl-nicotinic acid ethyl ester A mixture of θ-hydroxy-S-methyl-nicotinic acid ethyl ester (1.65 g, 9.11 mmol) in POCI3 (2.55 ml_, 27.3 mmol) was stirred at 1200C for 1.5 hour. The mixture was cooled down and poured into ice. The resulting precipitate was filtered off, washed with water and then solubilised in DCM. The organic phase was dried over sodium sulfate and then concentrated in vacuo to afford 6-chloro-5-methyl-nicotinic acid ethyl ester (1.55 g, 85%) as a dark brown solid. (ES- MS: m/z 241.1/243.1 [M+CH3CN+H]\ tR 5.12 min (system 2)).
iv) 5-Methyl-6-(6-methyl-pyridin-3-ylamino)-nicotinic acid ethyl ester
A mixture of θ-chloro-δ-methyl-nicotinic acid ethyl ester (750 mg, 3.76 mmol), 3-amino-6- methyl pyridine (609 mg, 5.64 mmol), Pd(OAc)2 (26 mg, 0.11 mmol), rac-BINAP (72 mg, 0.11 mmol) and potassium carbonate (2.62 g, 18.8 mmol) in degassed toluene (20 ml_) was stirred, under argon, at 800C for 4 hours. EtOAc was added and the organic phase was washed with water, dried over sodium sulfate and concentrated in vacuo to afford the 5- methyl-6-(6-methyl-pyridin-3-ylamino)-nicotinic acid ethyl ester (1.02 g, 100%) as a black solid. (ES-MS: m/z 272.2 [M+H]\ tR 3.37 min (system 2)).
v) 5-Methyl-6-(6-methyl-pyridin-3-ylamino)-nicotinic acid
To a solution of 5-methyl-6-(6-methyl-pyridin-3-ylamino)-nicotinic acid ethyl ester (1.02 g,
3.76 mmol) in THF/MeOH (1/1, 40 mL), NaOH 2N (3.8 ml_, 7.6 mmol) was added. The mixture was stirred at RT for 16 hours. The solvent was removed in vacuo and the crude was diluted with water. The aqueous was acidified to pH 4-5 by addition of HCI 2N. The resulting precipitate was removed by filtration and dried under high-vacuum to afford 5- methyl-6-(6-methyl-pyridin-3-ylamino)-nicotinic acid (615 mg, 67%) as a beige solid. (ES-MS: m/z 2AA A [M+H]\ tR 2.77 min (system 2)).
Example 9.2: r5-Fluoro-6-(6-methvl-pvridin-3-ylamino)-pyridin-3-yll~piperidin-1-yl-methanone [5-Fluoro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-piperidin-1 -yl-methanone was prepared following the procedure described in example 9.1.
TLC: Rf = 0.14 (EtOAc/hexanes 1 :9), LC/MS: m/z = 315 (MH+).
The starting material can be prepared as described in example 9.1.v) and iv) starting from 6- Chloro-5-fluoro-nicotinic acid methyl ester.
Example 10: Biological Testing. Activity of compounds of the present invention was examined by measurement of the inhibition of the glutamate induced elevation of intracellular Ca2*-concentration following similar methods than those described in L. P. Daggett et al., Neuropharm. Vol. 34, pages 871-886 (1995), P. J. Flor et al., J. Neurochem. Vol. 67, pages 58-63 (1996).
The table below represents percentages of inhibition of the glutamate induced elevation of intracellular Ca ,2+ -concentration at a concentration of 10 μM.
Figure imgf000062_0001
Figure imgf000062_0002
Figure imgf000063_0001
Figure imgf000063_0002
Figure imgf000064_0002
Figure imgf000064_0001

Claims

1. A compound of formula (I)
Figure imgf000065_0001
wherein
R1 represents optionally substituted Alkyl or optionally substituted Benzyl and
R2 represents Hydrogen (H), optionally substituted Alkyl or optionally substituted Benzyl; or
R1 and R2 form together with the Nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms;
R3 represents Halogen, Hydroxy (OH), Alkyl, Alkoxy, Amino, Alkylamino, Dialkylamino;
R4 represents Hydroxy (OH), Halogen, Amino, Alkylamino, Dialkylamino Alkyl, Alkoxy; Q represents CH, CR4, N;
V represents CH, CR4, N; W represents CH, CR4, N; X represents CH, N;
Y represents CH, CR3, N; Z represents CR6aR6b, NR5, O;
R5 represents Hydrogen, Hydroxy (OH);
R6a and R6b are each independently selected from Hydrogen, Halogen, Hydroxy (OH),
Amino, Alkyl, Alkoxy, Haloalkyl; and provided that Q1 V, W are not N at the same time, in free base or acid addition salt form.
2. A compound of formula (II)
Figure imgf000065_0002
wherein Q represents CH1 CR4, N;
V represents CH, CR4, N;
W represents CH, CR4, N;
X represents CH, N; Y represents CH, CR3, N;
Z represents CR63R65, NR5, O;
R1 represents optionally substituted Alkyl or optionally substituted Benzyl and
R2 represents Hydrogen (H), optionally substituted Alkyl or optionally substituted Benzyl; or R1 and R2 form together with the Nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms;
R3 represents Halogen, Hydroxy (OH), Alkyl, Alkoxy, Amino, Alkylamino, Dialkylamino;
R4 represents Hydroxy (OH), Halogen, Amino, Alkylamino, Dialkylamino Alkyl, Alkoxy;
R5 represents Hydrogen, Hydroxy (OH); R6a and R6b are each independently selected from Hydrogen, Halogen, Hydroxy (OH),
Amino, Alkyl, Alkoxy, Haloalkyl; and provided that Q, V, W are not N at the same time and provided that at least one Q, V, W represents N, in free base or acid addition salt form.
3. In yet a further aspect, the invention relates to new compounds of formula (III)
Figure imgf000066_0001
wherein
Q represents CH, CR4, N; V represents CH, CR4, N;
W represents CH, CR4, N;
X represents CH, N;
Y represents CR3;
Z represents CR6aR6b, NR5, O; R1 represents optionally substituted Alkyl or optionally substituted Benzyl and
R2 represents Hydrogen (H), optionally substituted Alkyl or optionally substituted Benzyl; or R1 and R2 form together with the Nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms;
R3 represents Halogen, Hydroxy (OH), Alkyl, Alkoxy, Amino, Alkylamino, Dialkylamino; R4 represents Hydroxy (OH), Halogen, Amino, Alkylamino, Dialkylamino Alkyl, Alkoxy; R5 represents Hydrogen, Hydroxy (OH);
R6a and R6b are each independently selected from Hydrogen, Halogen, Hydroxy (OH), Amino, Alkyl, Alkoxy, Haloalkyl; and provided that Q, V, W are not N at the same time and provided that at least one Q, V, W represents N, in free base or acid addition salt form.
4. A compound of any one of claims 1 , 2 or 3 having the formula (IV)
Figure imgf000067_0001
R1 represents optionally substituted Alkyl or optionally substituted Benzyl and
R2 represents Hydrogen (H), optionally substituted Alkyl or optionally substituted Benzyl; or
R1 and R2 form together with the Nitrogen atom to which they are attached an optionally substituted heterocycle with less than 14 ring atoms; R3 represents Halogen, Alkyl, Alkoxy, Amino, Alkylamino, Dialkylamino; and
R4 represents Hydroxy (OH), Halogen, Alkyl, Alkoxy.
5. A compound of claim 1 , which is selected from the groups comprising:
6-(4-Chloro-phenylamino) -N, N-diethyl-nicotinamide hydrochloride N, N-Diethyl-6-p-tolylamino-nicotinamide hydrochloride
N,N-Diethyl-6-(4-methoxy-phenylamino)-nicotinamide hydrochloride
6-(4-Chloro-phenylamino)-N,N-bis-(2-methoxy-ethyl)-nicotinamide hydrochloride
[6-(4-Chloro-3-fluoro-phenylamino) -pyridin-3-yl]-piperidin- 1 -yl-methanone [6-(4-Bromo-phenylamino)-pyridin-3-yl]-piperidin-1-yl-methanone
4-[5-(Piperidine~1-carbonyl)-pyridin-2-ylamino]-benzonitrile
Piperidin-1-yl-[6-(4-trifluoromethoxy-phenylamino)-pyridin-3-yl]-methanone
[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(2-methyl-piperidin-1-yl)-methanone hydrochloride
(2-Methyl-pipehdin-1-yl)-(6-p-tolylamino-pyridin-3-yl)-methanone
[6-(4-Methoxy-phenylamino)-pyridin-3-yl]-(2-methyl-pipehdin-1-yl)-methanone hydrochloride
rac-[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(3-methyl-piperidin-1-yl)-methanone
[6-(4-Chloro-phenylamino)-pyήdin-3-yl]-(S-3-methyl-piperidin-1-yl)-methanone
[6-(4-Chloro-phenylamino)-pyhdin-3-yl]-(R-3-methyl-pipehdin-1-yl)-methanone
3-Methyl-piperidin-1-yl)-(6-p-tolylamino-pyridin-3-yl)-methanone
[6-(4-Methoxy-phenylamino)-pyridin-3-yl]-(3-methyl-piperidin-1-yl)-methanone hydrochloride
(3-Methyl-piperidin-1-yl)-(6-phenylamino-pyridin-3-yl)-methanone
[6-(3-Chloro-phenylamino)-pyridin-3-yl]-(3-methyl-piperidin-1-yl)-methanone hydrochloride
[6-(4-Chloro-phenylamino)-pyridin-3-yl]-morpholin-4-yl-methanone hydrochloride
[6-(4-Methoxy-phenylamino)-pyridin-3-yl]-morpholin-4-yl-methanone hydrochloride
cis-[6-(4-Chloroφhenylamino)-pyridin-3--yl]-(2,6-dimethyl-morpholin-4-yl)-methanone hydrochloride
(cis-2,6-Dimethyl-morpholin-4-yl)-(6-p-tolylamino-pyridin-3-yl)-methanone hydrochloride
(cis-2,6'Dimethyl-morpholin-4-yl)-[6-(4-methoxy-phenylamino)-pyridin-3-yl]-methanone hydrochloride
[6-(5-Chloro-pyridin-2-ylamino)-pyridin-3-yl]-piperidin-1-yl-methanone
Azepan-1-yl-[6-(pyridin-3-ylamino)-pyridin-3-yl]-methanone
[6-(3, 4-Difluoro-phenylamino) -pyridin-3-ylJ-piperidin- 1 -yl-methanone rac-(2'Aza-bicyclo[2.2.1]hept-2-yl)-[5-chloro-6-(4-chloro-phenylamino)-pyridin-3-yl]- methanone
[5-Chloro-6-(4-chloro-phenylamino)-pyridin-3-yl]-thiomoφholin-4-yl-methanone
rac-fδ-Chloro-β-fβ-methoxy-pyridin-S-ylaminoj-pyridinS-ylJ-fS-methyl-piperidin-i-yl)- methanone
Azepan-1-y\-[5-ch\oro-6-{6-methoxy-pyndin-3-y\amino)-pynd\n-3-y\]-methanone
[S-Chloro-β-fβ-methoxy-pyridin-d-ylaminoj-pyridinS-ylJ-piperidin-i-yl-methanone
[5-Chloro-6-(6-ethoxy-pyridin-3-ylamino)-pyridin-3-yl]-pipehdin-1-yl-methanone
rac-tS-Chloro-β-fβ-methyl-pyridinS-ylaminoϊ-pyridin-S-ylJ-fS-methyl-piperidin-i-yl)- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(S-3-methyl-piperidin-1-yl)-methanone
[S-Chloro-β-fβ-methyl-pyridin-S-ylaminoypyridin-S-ylJ-fRS-methyl-piperidin-i-yty-methanone
[5-Chloro-6-(6-methy\-pyridin-3-y\aminό)-pyήdin-3-y\]-piperidin-1-y\-methanone
Azepan-1-yl-[5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-methanone
rac-(2-Aza-bicyclo[2.2.1]hept-2-yl)-[5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]- methanone
[5-Ch\oro-Q-(Q-methy\-pyήdin-3-y\aminό)-pyήdin-3-y\]-thiazo\idin-3-y\-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-thiomorpholin-4-yl-methanone
[5-Chloro-6-(2-methyl-pyrimidin-5-ylamino)-pyήdin-3-yl]-(3-methyl-piperidin-1-yl)-methanone
[5-Chloro-6-(2-methyl-pyrimidin-5-ylamino)-pyridin-3-yl]-piperidin-1-yl-methanone
Azepan-1-yl-[5-chloro-6-(2-methyl-pyrimidin-5-ylamino)-pyridin-3-yl]-methanone [δ-Chloro-β-fβ-methyl-pyridin-S-ylaminoypyridinS-ylJ-β-ethyl-piperidin-i-yO-methanone
[5-Ch\oro-Q-(Q-methoxy-pyndin-3-ylamino)-pyridin-3-y\]-(3-ethy\-piperidin-1-yi)-methanone
[5-Chloro-6-(4-chloro-phenylamino)-pyridin-3-yl]-(3-ethyl-piperidin-1-yl)-methanone [5-Chloro~6-(&methylφyridin-3-ylamino)-pyridin-3-yl]-(3-propyl-piperidin-1-yl)-methanone
[5-Chloro-6-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-3-yl]-((R)-2-ethyl-piperidin-1-yl)- methanone
[5-Chloro-6-(6-methoxy-pyridin-3-ylamino)-pyridin-3-yl]-((R)-2-ethyl-pipehdin-1-yl)- methanone
rac-[5-Chloro-6-(6-methyl-pyridin-3-yloxy)-pyridin-3-yl]-(3-methyl-piperidin-1-yl)-methanone
[5-Chloro-6-(6-methyl-pyridin-3-yloxy)-pyridin-3-yl]-piperidin-1-yl-methanone
Azepan-1-yl-[5-chloro-6-(6-methyl-pyridin-3-yloxy)-pyhdin-3-yl]-methanone
[6-(6-Methyl-pyridin-3-ylamino)-pyhdin-3-yl]-piperidin-1-yl-methanone
Azepan-1-yl-[6-(4-chloro-phenylamino)-pyridin-3-yl]-methanone
[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(3,3-difluoro-piperidin-1-yl)-
methanone
[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(4-methyl-pipeήdin-1-yl)-methanone
[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(3,5-dimethyl-piperidin-1-yl)-methanone
rac-[6-(4-Chloro-phenylamino)-pyhdin-3-yl]-(3-hydroxymethyl-piperidin-1-yl)-methanone
rac-[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(3-methoxy-piperidin-1-yl)-methanone
[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(octahydro-quinolin-1-yl)-meth
anone (diastereomeric mixture, cis / trans)
(3-Aza-bicyclo[3.2.2]non-3-yl)-[6-(4-chloro-phenylamino)-pyήdin-3-yl]-methanone
(2-Aza-tricyclo[3.3.1.1 *3, 7*]dec-2-yl)-[6-(4-chloro-phenylamino)-pyridin-3-yl]-methanone
[6-(4-Chloro-phenylamino)-pyridin-3-yl]-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-methanone
rac-(2-Aza-bicyclo[2.2.1]hept-2-yl)-[6-(4-chloro-phenylamino)-pyridin-3-yl]-methanone
rac-(3-Methyl-piperidin-1-yl)-[6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-methanone
(S-3-Methyl-piperidin-1-yl)-[6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-methanone (R-3-Methyl-piperidin-1-yl)-[6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-methanone
[6-(4-Chloro-phenylamino)-pyridin-3-yl]~(rel-(3aR,4S,7aR)-4-hydroxy-4-m-tolylethynyl- octahydro-indol-1-yl)-methanone
Azepan-1-yl-[6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-methanone
Azocan-1-yl-[6-(6-methyl-pyridin-3-ylamino)-pyridin-3'yl]-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-ethyl-piperidin-1-yl)-methanone
[δ-Chloro-β-fβ-methyl-pyridin-S-ylaminoj-pyridin-S-ylJ-tfR^-ethyl-piperidin-i-yQ-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((S)-2-ethyl-piperidin-1-yl)-m
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyhdin-3-yl]-(2,3-dimethyl-pipehdin-1-yl)- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((2S, 3S)-2, 3-dimethyl-piperidin- 1 -yl)- methanone
[5-Chloro-6-(6-methylφyήdin-3-ylamino)-pyridin-3-yl]-((2R,3R)-2,3-dimethyl-piperidin-1^ methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((S)-2-methyl-piperidin- 1-yl)- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((R)-2-methyl-piperidin-1-yl)- methanone
[δ-Chloro-β-fβ-methyl-pyridin-d-ylaminoj-pyridin-S-ylJ-foctahydro-liJpyrindin-i-yl)- methanone
[δ-Chloro-β-iβ-methyl-pyridinS-ylaminoϊ-pyridin^-ylJ-ftaSJaSΪ-octahydro-liJpyrindin-i-yl- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyήdin-3-yl]-(4aR,7aR)-octahydro-[1]pyrindin-1-yl- methanone
[5-Ch\oro-6-{Q-methy\-pyr\dm' -3-y\amino)-pyήd\n-3-y\]-(2-isopropy\-p\peridin-1-y\)-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((R)-2-isopropyl-piperidin-1-yl)- methanone [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((S)-2-isopropyl-piperidin-1-yl)- methanone
[δ-Chloro-β-f&methyl-pyridin-S-ylaminoj-pyridin-S-ylJ-tfRyS-ethyl-piperidin-i-yO-methanone
[S-Chloro-β-fβ-methyl-pyridin-S-ylaminoj-pyridin-S-ylJ-ffSJS-ethyl-piperidin-i-ylj-methanone
[5-Chloro-6-(6-methyl-pyήdin-3-ylamino)-pyήdin-3-yl]-(3-cyclopropyl-piperidin-1-yl)- methanone
[5-Chloro-6-(&methyl-pyndin-3-ylamino)-pyridin-3-yl]-(2-propyl-pipendin-1-yl)-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((S)-2-propyl-piperidin-1-yl)- methanone
[S-Chloro-β-fβ-methylφyridin-S-ylaminoypyridin-S-ylJ-ffRy∑-propyl-piperidin-i-yO-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2,3-diethyl-pipeήdin-1-yl)-methanone
(2-Butyl-piperidin-1-yl)-[5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyhdin-3-yl]-methanone
[5-Chloro-6-(6-methylφyridin-3-ylarnino)-pyridin-3-yl]-[2-(1-ethyl-propyl)-piperidin-1-yl]- methanone
[5-Chloro~&(6-methyl-pyridin-3-ylamino)φyridin-3-yl]-(2-ethyl-3-methyl-piperidin-1-yl)- methanone
[5-Chloro-6-{6-methy\-pyrid\n-3-y\am\no)φyr\din-3-y\]-(2-pheny\-piper\dm' -1-y\)-methanone
[5-Ch\oro-Q-(6-meihy\-pyήd\n-3-y\ammo)-pyήd\n-3-y\]-{3A,5£4etrahydro-^^ 1-yl)-methanone
[5-Chloro-&(6-methylφyridin-3-ylamino)φyήdin-3-yl]-(3A,5,6-tetrahydro-2H-[2,3']bipyridiny^ 1-yl)-methanone
[S-Chloro-β-fβ-methyl-pyridin-S-ylaminoj-pyridinS-ylJ-^tetrahydro-furan^-yO-piperidin-i- yl]-methanone
[5-Chloro-6-(6-methylφyridin-3-ylamino)-pyridin-3~yl]-[2-(5-methyl-furan-2-yl)-piperidin-1-yl]- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-oxazol-2-yl-pipehdin-1-yl)- methanone β-fi-Chloro-ethyiypiperidin-i-yiπδ-chloro-β-fβ-methyl-pyridin-S-ylaminoj-pyridin-S-yl]- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2,6-dimethyl-piperidin-1-yl)- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2, 2, 6, 6-tetramethyl-piperidin-1-yl)- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-methyl-6-ropyl-piperidin-1-yl)- methanone
[δ-Chloro-β-fβ-methyl-pyridin-d-ylaminoypyridinS-ylJ-^R.βR^-ethyl-β-propyl-piperidin-i- yl)-methanone
[5-Chloro-&(6-methylφyridin-3-ylamino)-pyridin-3-yl]-(5-methyl-2-ropyl-piperidin-1-yl)- methanone
[5-Chlorch6-(4-chloro-phenylamino)-pyridin-3-yl]-(octahydro-1]pyrindin-1-yl)-methanone
[5-Chloro-6-(4-chloro-phenylamino)-pyridin-3-yl]-((R)-2-ethyl-piperidin-1-yl)-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)φyridin-3-yl]-(2-vinyl-piperidin-1-yl)-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-[((Z)-2-propenyl)-piperidin-1-yl]- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-[3-ethylidene-pipeήdin-1-yl]-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyήdin-3-yl]-[3-propylidene-pipeήdin-1-yl]- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-ethoxymethyl-piperidin-1-yl)- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-thoxymethyl-piperidin-1-yl)- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyhdin-3-yl]-[2-(2-hydroxy-ethyl)-pipeήdin-1-yl]- methanone [5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(5-flυoro-2-propyl-piperidin-1-yl)- methanone
[5-Chloro-6-(6-methyl-pyndin-3-ylamino)-pyridin-3-yl]-[2-(1,2-difluoro-propyl)-piperidin-1-yl]- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-[2-(2-fluoro-propyl)-piperidin-1-yl]- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-ethyl-[1,3]o
xazepan-3-yl)-methanone
[5-Chloro-6-(6-methyl-pyridin-3~ylamino)-pyridin-3-yl]-(2-propyl-[1,3]oxazepan-3-yl)- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-[2-(1-ethyl-propyl)-[1,3]oxazepan-3-yl]- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-propyl-[1,3]oxazinan-3-yl)- methanone
fi-Chloro-β-fβ-methyl-pyridin-S-ylaminoypyridin-S-yll-β-fi-ethyl-propylHI.SJoxazinanS-yl]- methanone
(2-Bυtyl-[1,3]oxazinan-3-yl)-[5-chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-[2-(2-methoxy-ethyl)-piperidin-1-yl]- methanone
[S-Chloro-β-fβ-methyl-pyridin-S-ylaminoypyridinS-ylJ-ft-phenyl-pyrrolidin-i-ylj-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-pyridin-2-yl-pyrrolidin-1-yl)- methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-((R)-2-ethoxy-pyrrolidin-1-yl)- methanone
[δ-Chloro-β-fβ-methyl-pyhdin-S-ylaminoypyridin-d-ylJ-^-fδ-methyl-thiophen^-yO-pyrrolidin-i- ylj-methanone
[5-Chloro-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-(2-propyl-azepan-1-yl)-methanone [5-Chlorch6-(6-methyl-pyridin-3-ylamino)-pyήdin-3-yl]-(3φropyl-moφholin-4-yl)-methanone
rac-[5-Chloro-6-(4-chloro-phenylamino)φyridin-3-yl]-(3-methylφiperidin-1-yl)-methanone
[5-Chloro-6-(4-chloro-phenylamino)-pyridin-3-yl]-(S-3-methyl-piperidin-1-yl)-methanone [5-Chloro-6-(4-chloro-phenylamino)-pyridin-3-yl]-(R-3-methyl-pipehdin-1-yl)-methanone Azepan-1-yl-[2-(4-chloro-phenylamino)-pyrimidin-5-yl]-methanone
[2-(4-Chloro-phenylamino)-pyrimidin-5-yl]-piperidin-1-yl-methanone
rac-β-μ-Chloro-phenylaminoj-pyrimidin-δ-ylJ-fS-methylφiperidin-i-ylj-methanone Azepan-1-yl-[6-(4-chloro-phenylamino)-5-methoxy-pyridin-3-yl]-methanone Azepan-1-yl-[5-methoxy-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-methanone] [6-(4-Chloro-phenylamino)-5-methoxy-pyridin-3-yl]-piperidin-1-yl-methanone
[5-Methoxy-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-piperidin-1-yl-methanone Azepan-1-yl-[6-(4-chloro-phenylamino)-5-ethoxy-pyridin-3-yl]-methanone Azepan-1-yl-[5-ethoxy-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-methanone [5-Ethoxy-6-(6-methyl^yridin-3-ylamino)-pyridin-3-yl]-piperidin-1-yl-methanone [5-Chloro-6-(6^hloroφyridin-3-ylamino)-pyridin-3-yl]-(3-methyl-piperidin-1-yl)-methanone
[6-(4-Chloro-phenylamino)-pyridazin-3-yl]-piperidin-1-yl-methanone rac-fβ-ft-Chloro-phenylaminoypyridazin-S-ylJ-fi-methyl-piperidin-i-yiymethanone [6-(4-Chloro-phenylamino)-pyridazin-3-yl]-(3,3-dimethyl-piperidin-1-yl)-methanone [6-(4-Chloroφhenylamino)-pyhdazin-3-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone [6-(4-Chloro-phenylamino)-pyridazin-3-yl]-(4-methyl-piperidin-1-yl)-methanone [5-Methyl-6-(6-methyl-pyridin-3-ylamino)-pyridin-3-yl]-piperidin-1-yl-methanone [5-Fluoro-6-(6-methyl-pyridin-3-ylamino)-pyήdin-3-yl]-piperidin-1-yl-methanone
6. A process for the preparation of a compound of claim 1 , 2 or 3, or a salt thereof,
a) wherein Z represents NH or O, comprises the step of reacting a compound of formula (ii)
Figure imgf000076_0001
wherein R1 and R2 are as defined above, LG represents a leaving group with a compound of formula (iii)
Figure imgf000076_0002
wherein Q, V1 W is as defined above and Z represents NH or O, and recovering the resulting compound of formula (I), (II), (III) or (IV) in free base or acid addition salt form
or
b) wherein Z represents CH2, comprises the step of reacting a compound of formula (ii)
Figure imgf000076_0003
wherein R1 and R2 are as defined in claim 2, LG represents a leaving group, with a compound of formula (vi)
Figure imgf000076_0004
wherein Q, V, W is as defined above and Z, optionally in the presence of a reaction auxiliary, and recovering the resulting compound of formula (I), (II), (III) or (IV) in free base or acid addition salt form.
7. A compound of any one of claims claim 1 to 5 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
8. A compound of any one of claims claim 1 to 5 in free base or pharmaceutically acceptable acid addition salt form, for use in the prevention, treatment or delay of progression of disorders associated with irregularities of the glutamatergic signal transmission, and of nervous system disorders, and of Gl, Urinary tract disorders mediated full or in part by mGluR5.
9. A pharmaceutical composition comprising a compound of any one of claims claim 1 to 5 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent .
10. The use of a compound of any one of claims claim 1 to 5 in free base or pharmaceutically acceptable acid addition salt form, in the prevention, treatment or delay of progression of disorders associated with irregularities of the glutamatergic signal transmission, and of nervous system disorders, and of Gl, Urinary tract disorders mediated full or in part by mGluR5.
11. The use of a compound of any one of claims claim 1 to 5 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a pharmaceutical composition designed for the prevention, treatment or delay of progression of disorders associated with irregularities of the glutamatergic signal transmission, and of nervous system disorders, and of Gl, Urinary tract disorders mediated full or in part by mGluR5.
12. A method of the prevention, treatment or delay of progression of disorders associated with irregularities of the glutamatergic signal transmission, and nervous system disorders , and of Gl, Urinary tract disorders mediated full or in part by mGluR5, which method comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of any one of claims claim 1 to 5 in free base or pharmaceutically acceptable acid addition salt form.
PCT/EP2006/012181 2005-12-20 2006-12-18 Nicotinic acid derivatives as modulators of metabotropic glutamate receptors WO2007071358A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP06829702A EP1966144A1 (en) 2005-12-20 2006-12-18 Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
CA002627630A CA2627630A1 (en) 2005-12-20 2006-12-18 Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
AU2006329007A AU2006329007A1 (en) 2005-12-20 2006-12-18 Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
JP2008546217A JP2009519986A (en) 2005-12-20 2006-12-18 Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
BRPI0620066-4A BRPI0620066A2 (en) 2005-12-20 2006-12-18 nicotinic acid derivatives as metabotropic glutamate receptor modulators, process for preparing them, pharmaceutical composition and use of said derivatives
US12/158,387 US20090005363A1 (en) 2005-12-20 2006-12-18 Organic Compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05027934 2005-12-20
EP05027934.8 2005-12-20
EP06120424 2006-09-11
EP06120424.4 2006-09-11

Publications (1)

Publication Number Publication Date
WO2007071358A1 true WO2007071358A1 (en) 2007-06-28

Family

ID=37744569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/012181 WO2007071358A1 (en) 2005-12-20 2006-12-18 Nicotinic acid derivatives as modulators of metabotropic glutamate receptors

Country Status (12)

Country Link
US (1) US20090005363A1 (en)
EP (1) EP1966144A1 (en)
JP (1) JP2009519986A (en)
KR (1) KR20080076962A (en)
AR (1) AR058554A1 (en)
AU (1) AU2006329007A1 (en)
BR (1) BRPI0620066A2 (en)
CA (1) CA2627630A1 (en)
PE (1) PE20071171A1 (en)
RU (1) RU2008129622A (en)
TW (1) TW200732323A (en)
WO (1) WO2007071358A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009019149A1 (en) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
WO2009047303A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of pervasive developmental disorder
WO2009047296A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Metabotropic glutamate receptor modulators for the treatment op parkinson's disease
WO2010000763A2 (en) * 2008-06-30 2010-01-07 Novartis Ag Combination products
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
WO2011009890A2 (en) 2009-07-23 2011-01-27 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
WO2011036167A1 (en) 2009-09-22 2011-03-31 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
WO2011161249A1 (en) 2010-06-24 2011-12-29 Novartis Ag Use of 1h-quinazoline-2,4-diones
US20120046243A1 (en) * 2010-08-23 2012-02-23 Syntrix Biosystems Inc. Aminopyridine- and Aminopyrimidinecarboxamides as CXCR2 Modulators
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012085166A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012101060A1 (en) 2011-01-27 2012-08-02 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2013036224A1 (en) 2011-09-07 2013-03-14 Novartis Ag Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
WO2014111751A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
US20140336374A1 (en) * 2008-12-19 2014-11-13 Boehringer Ingelheim International Gmbh Process and intermediates for the production of ccr2 antagonists
US9480694B2 (en) 2013-08-02 2016-11-01 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamide for use in treating pulmonary disease
US9670222B2 (en) 2009-12-17 2017-06-06 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10213428B2 (en) 2015-07-02 2019-02-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
USRE47415E1 (en) 2009-02-17 2019-06-04 Syntrix Biosystems, Inc. Pyrimidinecarboxamides as CXCR2 modulators
WO2019162391A1 (en) * 2018-02-23 2019-08-29 Westfälische Wilhelms-Universität Münster Method for producing fluorinated heterocyclic aliphatic compounds
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2470182B1 (en) 2009-08-24 2014-06-04 Neuralstem, Inc. Synthesis of a neurostimulative piperazine
WO2011035324A1 (en) * 2009-09-21 2011-03-24 Vanderbilt University O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
CN103037693A (en) * 2010-05-24 2013-04-10 范德比尔特大学 Substituted-6-methylnicotinamides as MGLUR5 positive allosteric modulators
NZ626744A (en) * 2011-12-22 2016-05-27 Connexios Life Sciences Pvt Ltd Derivatives of aza adamantane and uses thereof
TW201444821A (en) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv Substituted piperidine compounds and their use as orexin receptor modulators
TW201444849A (en) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv Substituted 7-azabicycles and their use as orexin receptor modulators
TWI621618B (en) 2013-03-13 2018-04-21 比利時商健生藥品公司 Substituted 2-azabicycles and their use as orexin receptor modulators
WO2015098991A1 (en) * 2013-12-26 2015-07-02 東レ株式会社 N-alkylamide derivative and medicinal use thereof
CN107108566B (en) * 2014-09-11 2020-11-24 詹森药业有限公司 Substituted 2-azabicyclic compounds and their use as orexin receptor modulators
US20190231525A1 (en) 2016-08-01 2019-08-01 Mitraltech Ltd. Minimally-invasive delivery systems

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE817911C (en) * 1947-12-16 1951-10-22 Chem Fab Tempelhof Preuss & Te Process for the preparation of pyridine-3-carboxamides which are basically substituted in the 6-position
WO1999018096A1 (en) * 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO1999026927A2 (en) * 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
EP1026149A1 (en) * 1997-10-02 2000-08-09 Sankyo Company Limited Amidocarboxylic acid derivatives
WO2000073283A1 (en) * 1999-06-02 2000-12-07 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
WO2001007416A1 (en) * 1999-07-28 2001-02-01 Lonza Ag Method of producing pyridazine carboxylic acid derivatives
WO2004026305A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist
WO2004032908A2 (en) * 2002-10-04 2004-04-22 Abbott Laboratories Method of inhibiting angiogenesis
WO2005105759A1 (en) * 2004-04-28 2005-11-10 Grünenthal GmbH Substituted 5, 6, 7, 8-tetrahydro-pyrido[4, 3-d]pyrimidine-2-yl compounds and 5, 6, 7, 8-tetrahydro-quinazoline-2-yl compounds
WO2006014134A1 (en) * 2004-08-02 2006-02-09 Astrazeneca Ab Novel piperidine derivative for the treatment of depression
WO2006053120A1 (en) * 2004-11-12 2006-05-18 Bristol-Myers Squibb Company IMIDAZO-FUSED THIAZOLO[4,5-b]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
WO2006064286A1 (en) * 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1381603A2 (en) * 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US7115741B2 (en) * 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
CA2551178C (en) * 2003-12-24 2012-11-06 Biota Scientific Management Pty Ltd Polycyclic agents for the treatment of respiratory syncytial virus infections
US7253168B2 (en) * 2004-04-07 2007-08-07 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
WO2006094639A1 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Pyridine-2-carboxamide derivatives as mglur5 antagonists

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE817911C (en) * 1947-12-16 1951-10-22 Chem Fab Tempelhof Preuss & Te Process for the preparation of pyridine-3-carboxamides which are basically substituted in the 6-position
WO1999018096A1 (en) * 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1026149A1 (en) * 1997-10-02 2000-08-09 Sankyo Company Limited Amidocarboxylic acid derivatives
WO1999026927A2 (en) * 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
WO2000073283A1 (en) * 1999-06-02 2000-12-07 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
WO2001007416A1 (en) * 1999-07-28 2001-02-01 Lonza Ag Method of producing pyridazine carboxylic acid derivatives
WO2004026305A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist
WO2004032908A2 (en) * 2002-10-04 2004-04-22 Abbott Laboratories Method of inhibiting angiogenesis
WO2005105759A1 (en) * 2004-04-28 2005-11-10 Grünenthal GmbH Substituted 5, 6, 7, 8-tetrahydro-pyrido[4, 3-d]pyrimidine-2-yl compounds and 5, 6, 7, 8-tetrahydro-quinazoline-2-yl compounds
WO2006014134A1 (en) * 2004-08-02 2006-02-09 Astrazeneca Ab Novel piperidine derivative for the treatment of depression
WO2006053120A1 (en) * 2004-11-12 2006-05-18 Bristol-Myers Squibb Company IMIDAZO-FUSED THIAZOLO[4,5-b]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
WO2006064286A1 (en) * 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Interchim Intermediates", 18 January 2005, INTERCHIM, MONTLUCON, 03103, FRANCE *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002421940 *
KURAMOCHI T ET AL: "Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 13, no. 12, 2 June 2005 (2005-06-02), pages 4022 - 4036, XP004903737, ISSN: 0968-0896 *
KURAMOCHI T ET AL: "Synthesis and structure-activity relationships of 6-{4-[(3-fluorobenzyl)oxy]phenoxy}nicotinamide derivatives as a novel class of NCX inhibitors: a QSAR study", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 13, no. 3, 1 February 2005 (2005-02-01), pages 717 - 724, XP004710836, ISSN: 0968-0896 *
KURAMOCHI T ET AL: "Synthesis and structure-activity relationships of benzyloxyphenyl derivatives as a novel class of NCX inhibitors: effects on heart failure", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 13, no. 3, 1 February 2005 (2005-02-01), pages 725 - 734, XP004710837, ISSN: 0968-0896 *
KURAMOCHI T ET AL: "Synthesis and structure-activity relationships of phenoxypyridine derivatives as novel inhibitors of the sodium-calcium exchanger", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 12, no. 19, 1 October 2004 (2004-10-01), pages 5039 - 5056, XP004558883, ISSN: 0968-0896 *
TILLEY J W ET AL: "A Palladium-Catalyzed Carbonyl Insertion Route to Pyrido[2,1-b]quinazoline Derivatives", JOURNAL OF ORGANIC CHEMISTRY, vol. 52, 1987, pages 2469 - 2474, XP002421924 *
ZHU Y ET AL: "Cycloauration of substituted 2-phenoxypyridine derivatives and X-ray crystal structure of gold, dichloro[2-[[5-[(cyclopentylamino)carbonyl ]-2-pyridinyl-kappaN]oxy]phenyl-kappaC]- , (SP-4-3)-", JOURNAL OF ORGANOMETALLIC CHEMISTRY, ELSEVIER-SEQUOIA S.A. LAUSANNE, CH, vol. 677, no. 1-2, 1 July 2003 (2003-07-01), pages 57 - 72, XP004433247, ISSN: 0022-328X *

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
US8008305B2 (en) 2007-08-03 2011-08-30 Hoffmann-La Roche Inc. TAAR1 ligands
CN101784515A (en) * 2007-08-03 2010-07-21 弗·哈夫曼-拉罗切有限公司 Pyridinecarboxamide and benzamide derivatives as taar1 ligands
KR101167773B1 (en) * 2007-08-03 2012-07-24 에프. 호프만-라 로슈 아게 Pyridinecarboxamide and benzamide derivatives as taar1 ligands
WO2009019149A1 (en) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
WO2009047303A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of pervasive developmental disorder
WO2009047296A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Metabotropic glutamate receptor modulators for the treatment op parkinson's disease
WO2009047296A3 (en) * 2007-10-12 2009-08-20 Novartis Ag Metabotropic glutamate receptor modulators for the treatment op parkinson's disease
WO2009047303A3 (en) * 2007-10-12 2009-08-27 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of pervasive developmental disorder
JP2014240425A (en) * 2007-10-12 2014-12-25 ノバルティス アーゲー Metabotropic glutamate receptor modulator for the treatment of parkinson's disease
KR101572280B1 (en) * 2007-10-12 2015-11-26 노파르티스 아게 Metabotropic glutamate receptor modulators for the treatment of parkinson's disease
JP2011500529A (en) * 2007-10-12 2011-01-06 ノバルティス アーゲー Metabotropic glutamate receptor modulator for the treatment of Parkinson's disease
WO2010000763A3 (en) * 2008-06-30 2010-02-25 Novartis Ag Combinations comprising mglur modulators for the treatment of parkinson's disease
JP2011526596A (en) * 2008-06-30 2011-10-13 ノバルティス アーゲー Combination product
WO2010000763A2 (en) * 2008-06-30 2010-01-07 Novartis Ag Combination products
EP2826478A1 (en) 2008-06-30 2015-01-21 Novartis AG Combinations comprising mglur modulators for the treatment of parkinson's disease
US8703809B2 (en) 2008-06-30 2014-04-22 Novartis Ag Combination products
RU2496494C2 (en) * 2008-06-30 2013-10-27 Новартис Аг COMBINATIONS CONTAINING mGluR MODULATORS FOR TREATING PARKINSON'S DISEASE
US9067951B2 (en) * 2008-12-19 2015-06-30 Boehringer Ingelheim International Gmbh Process and intermediates for the production of CCR2 antagonists
US20140336374A1 (en) * 2008-12-19 2014-11-13 Boehringer Ingelheim International Gmbh Process and intermediates for the production of ccr2 antagonists
USRE47415E1 (en) 2009-02-17 2019-06-04 Syntrix Biosystems, Inc. Pyrimidinecarboxamides as CXCR2 modulators
WO2011009890A2 (en) 2009-07-23 2011-01-27 Novartis Ag Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
WO2011036167A1 (en) 2009-09-22 2011-03-31 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
US10537539B2 (en) 2009-09-22 2020-01-21 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
US11096916B2 (en) 2009-09-22 2021-08-24 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
US10196402B2 (en) 2009-12-17 2019-02-05 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US11046706B2 (en) 2009-12-17 2021-06-29 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US9670222B2 (en) 2009-12-17 2017-06-06 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US11731981B2 (en) 2009-12-17 2023-08-22 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
WO2011161249A1 (en) 2010-06-24 2011-12-29 Novartis Ag Use of 1h-quinazoline-2,4-diones
USRE48547E1 (en) 2010-08-23 2021-05-11 Syntrix Biosystems Inc. Aminopyrimidinecarboxamides as CXCR2 modulators
US8779149B2 (en) * 2010-08-23 2014-07-15 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
US8993541B2 (en) 2010-08-23 2015-03-31 Syntrix Biosystems, Inc. Aminopyrimidinecarboxamides as CXCR2 modulators
US20120046243A1 (en) * 2010-08-23 2012-02-23 Syntrix Biosystems Inc. Aminopyridine- and Aminopyrimidinecarboxamides as CXCR2 Modulators
USRE47740E1 (en) * 2010-08-23 2019-11-26 Syntrix Biosystems Inc. Aminopyridinecarboxamides as CXCR2 modulators
WO2012085166A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012101060A1 (en) 2011-01-27 2012-08-02 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2013036224A1 (en) 2011-09-07 2013-03-14 Novartis Ag Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
WO2014111837A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
WO2014111751A1 (en) 2013-01-15 2014-07-24 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
US10130645B2 (en) 2013-08-02 2018-11-20 Syntrix Biosystems, Inc. Use of thiopyrimidinecarboxamide for treating cancer
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US9707248B2 (en) 2013-08-02 2017-07-18 Syntrix Biosystems Inc. Use of thiopyrimidinecarboxamide for treating cancer
US9480694B2 (en) 2013-08-02 2016-11-01 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamide for use in treating pulmonary disease
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10993953B2 (en) 2013-08-02 2021-05-04 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10213428B2 (en) 2015-07-02 2019-02-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
US10568885B2 (en) 2015-07-02 2020-02-25 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-y1)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-citrate
US11147814B2 (en) 2015-07-02 2021-10-19 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p- tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
WO2019162391A1 (en) * 2018-02-23 2019-08-29 Westfälische Wilhelms-Universität Münster Method for producing fluorinated heterocyclic aliphatic compounds

Also Published As

Publication number Publication date
JP2009519986A (en) 2009-05-21
BRPI0620066A2 (en) 2011-11-01
RU2008129622A (en) 2010-01-27
EP1966144A1 (en) 2008-09-10
AU2006329007A1 (en) 2007-06-28
US20090005363A1 (en) 2009-01-01
KR20080076962A (en) 2008-08-20
AR058554A1 (en) 2008-02-13
PE20071171A1 (en) 2008-01-22
CA2627630A1 (en) 2007-06-28
TW200732323A (en) 2007-09-01

Similar Documents

Publication Publication Date Title
EP1966144A1 (en) Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
AU2007233669A1 (en) Novel bi-aryl amines
US20080269250A1 (en) Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists
US20090105266A1 (en) Organic compounds
AU2005300736B2 (en) Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
AU2007296964B2 (en) Nicotinic acid derivatives as modulators of metabotropic glutanate receptors
EP1877365A1 (en) Acetylene derivatives
AU2005300733A1 (en) Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1877367A1 (en) Acetylene derivatives
CA2631438A1 (en) Trisubstituted quinazolinone derivatives as vanilloid antagonists
KR101732989B1 (en) Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
WO2008107418A1 (en) Fused pyrimidinone compounds as mglur ligands
JP5264772B2 (en) Derivatives of pyrrolopyridine-2-carboxamide, their preparation and their therapeutic use
EP1655297A1 (en) Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
CN101321731A (en) Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
CA2213773A1 (en) Imidazopyridine derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680045162.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006829702

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3408/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2627630

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006329007

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/007880

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008546217

Country of ref document: JP

Ref document number: 1020087014836

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12158387

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006329007

Country of ref document: AU

Date of ref document: 20061218

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006329007

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008129622

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006829702

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0620066

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080619